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1.0 Introduction  
It has become common knowledge that many African health markets are trapped in a vicious cycle of 
a perennial disconnect between supply, demand and investments. According to the PharmAccess 
Foundation, and corroborated by numerous other sources, as of 2019, Africa has: more than 50% of 
all health expenses paid out of pocket; more than 80% of the global burden of non-communicable 
diseases; more than 15% of the world’s population; 47% of the global burden of communicable 
diseases; yet has less that 2% of global health expenditure (PAF, 2019). To compound this and the 
current burden for the health sector, the African continent will in the next few decades enter multiple 
transition phases that impact health security. These include demographic and disease transitions as 
populations age and as infectious diseases begin to be overshadowed by non-communicable diseases 
in addition to the impact of chronic infections on non-communicable diseases. All these changes will 
occur as industrial transitions and rural urban migration accelerate. 
 
As a (semi-) public good, healthcare requires large government intervention. However, many African 
countries suffer from limited state capabilities and poor institutions. On the other hand, despite its 
important role, the private sector is often weakly regulated and highly fragmented. The current 
health-industry complex (by which we mean the infrastructures and capabilities in place to 
manufacture, supply and deliver health products to patients) may not be adequate to address these 
emerging challenges. Put differently, the supply of medicines through manufacturing, procurement 
and distribution capabilities, and their dispensing to patients in health facilities of different forms, is 
presently not matching demand, and will only get more constrained with the challenges ushered in by 
multiple transitions. In response, therefore, African countries will not only need to accelerate local 
production of drugs, vaccines and other health technologies to be able to cater for emerging and long-
term health challenges the continent is facing and will face, but will also need new innovative business 
and funding models to attain and sustain competitiveness as well as social inclusion through a 
responsive and inclusive health industry complex. There is growing global evidence on the role and 
influence of public-private partnerships (PPPs) as a mechanism for availing the financing, capabilities 
and business models necessary for a health-industry complex that is good for socio-economic 
development. 
 
This paper reports on a study which sought to explore and understand the role that PPPs could play 
as viable technological catch-up vehicles and investment financing mechanisms for building a 
competitive African health sector that is interlinked with a vibrant pharmaceutical industry complex, 
capable of supplying drugs, vaccines and other health products that assure health inclusion and social 
security. In particular, this paper draws from co-produced primary and secondary qualitative and 
quantitative evidence from five southern African countries, namely Botswana, Namibia, South Africa, 
Zambia and Zimbabwe to highlight and examine examples, opportunities, successes, failures of and 
lessons from PPPs in health-industry innovation and health system financing. The rest of the paper is 
structured as follows: Section 2 gives an overview of the southern African the health sector and 
pharmaceutical context, followed by Section 3 which explores the history and role of PPPs. Section 4 
describes the rationale, conceptual framework and methodologies underpinning the study informing 
this paper, while Section 5 describes, analyses and discusses the findings from our case studies and 
Section 6 presents some conclusions and recommendations.  
 
2.0 Health in Southern Africa 
The five study countries are all members of the Southern African Development Community (SADC). 




within the context of Social and Human Development, Poverty and Food Security1. The region’s 
estimated 337.1 million inhabitants (2017 estimate) face high morbidity and mortality rates, low 
nutrition status, poor healthcare infrastructure and services and poor living conditions as major 
challenges. The region has for the past three decades faced a challenging and persistent HIV/AIDS 
pandemic, and it is not surprising that the pandemic permeates the entire plan as an issue that 
influences most factors of development in the region. The SADC region accounts for one-third of all 
people living with HIV and AIDS worldwide; while eight SADC Member States are among those 
countries with the highest rates of tuberculosis; and 75% of the SADC population is at risk of 
contracting malaria. It is estimated that the loss of productivity attributable to tuberculosis is up to 
7% of gross domestic product (GDP) for some countries, while the HIV/AIDS challenge depressed the 
GDP of most Sub-Saharan African countries by up to 20% in the decade 2001 to 2010 (WHO, 2013).  
 
This trio of diseases is a major threat to sustainable development in the region. As a result, a number 
of protocols, declarations, plans, and programmes have been developed to combat communicable 
diseases, led by the Social and Human Development and Special Programmes Directorate. The SADC 
Protocol on Health was established in 1999, and it oversees all of these declarations and strategic 
frameworks on health2. Article 9 of the Protocol on Health addresses communicable disease control, 
while Articles 10, 11, and 12 specifically concern HIV/AIDS, malaria, and tuberculosis. The Protocol on 
Health also covers a number of other issues critical to the preventative, diagnostic and curative 
functions of health delivery, among others; harmonisation of policies for disease definition, 
notification, and management and establishment in Member States of reference laboratories and 
sharing of information on diseases and epidemics.  
 
The health care systems of the five study countries, like elsewhere in the world, are continuously in 
need of strengthening due to challenges embedded in or transcending the systems (Mugwagwa, 
Banda and Chinyadza, 2017). The countries are all facing a number of similar challenges with respect 
to health delivery, presenting both objective and subjective reasons for inclusion in the study 
informing this paper. Specific country details will be presented in the findings section, suffice to say, 
across the five countries, there is an inexorable reality of countries that are individually and collectively 
confronted by a high and rising burden of disease; communicable and non-communicable diseases as 
well as perinatal and maternal disorders. The national health systems are characterized by relatively 




With respect to pharmaceuticals, the SADC region is fully awoken to the fact that use of appropriate 
pharmaceuticals is central to disease treatment and prevention, and that access to affordable, safe, 
and quality-assured medicines is uneven in Southern Africa4. There are a number of challenges 
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capabilities to meet the needs of the region, inefficient supply chains, an uncoordinated regulatory 
terrain, to lack of standardised legislation for pharmaceutical usage and disparate treatments for 
diseases.   
 
Among the five case study countries, there is a challenge of high cost of medicines due to factors 
related to, among others, logistical challenges, diminishing capacities of local pharmaceutical 
manufacturers, leading to reliance on imported medicines, particularly for Botswana, Namibia, Zambia 
and Zimbabwe (Mugwagwa, 2019). South Africa has accumulated industrial capabilities (or potential) 
for manufacturing medicines and a wide range of medical technologies. Its pharmaceutical industry is 
relatively well established when compared to the other SADC countries. Zimbabwe’s pharmaceutical 
manufacturing capabilities have shrunk considerably in the last two decades due to skills and capital 
flights in the backdrop of economic and political challenges (Banda, 2016?) 
 
The SADC Pharmaceutical Programme in June 2004 and now located within the Social and Human 
Development and Special Programmes Directorate takes care of the usage and treatment dimensions; 
while the SADC Pharmaceutical Programme aims to enhance the capacities of Member States to 
prevent and treat diseases of major concern to public health in the region, through improving access, 
affordability, and effectiveness of pharmaceuticals within the region (Article 29). A Business Plan for 
Essential Medicines has been put in place, which covers, among others; rationalising and maximising 
the research and production capacity of local and regional pharmaceutical industry of generic 
essential medicines and African Traditional Medicines; development of mechanisms to respond to 
emergency pharmaceutical needs (including procurement mechanisms); and strengthening regulatory 
capacity, supply, and distribution of basic pharmaceutical products through ensuring a fully functional 
regulatory authority with an adequate enforcement infrastructure.  
 
Innovations in the governance of the local production and distribution of medicines, diagnostics and 
a range of other health technologies  are  particularly key for ensuring full preparedness to deal with 
current and emerging health challenges, in turn putting the countries on the right path towards 
meeting Sustainable Development Goals (SDGs) in general and SDG3 on ‘Good Health and Well-being’ 
in particular. PPPs are seen as an opportunity for improving the health sector in general and the 
national health innovation system in particular through exploiting existing national industrial 
capabilities that are usually scattered across an institutional terrain comprising of R&D institutes, 
private large companies, local companies and SMEs (Gideon and Unterhalter, 2017).  
 
As noted by SADC and recognised across the countries, realisation of these improvements will involve 
various policy and institutional reforms to enable the countries to develop, utilize and expand their 
industrial capabilities for public health. Convergence of national health and industrial policy regimes 
as well as greater integration of innovation considerations into the national health policy framework 
are crucial considerations. Regulatory barriers, including those pertaining to registration of 
pharmaceuticals, diagnostics and medical devices, will need to be removed to facilitate innovation. 
Institutional adjustments (reform) will entail building greater linkages between industry and health 
care sectors. The nexus between health and industrialization is under-studied in Africa and other most 
developing countries (Mackintosh et al, 2018). There is scant empirical research on how industrial 
change (or industrial development) can aid (transform) public health, particularly in terms of reducing 
the costs of local manufacturing of medicines and medical equipment. This paper particularly focuses 
on providing new empirical data and evidence on how PPPs can play roles in the delivery of health and 
industrial policies and programmes for health and well-being. 
 
3.0 Public-Private Partnerships 
Van Ham and Koppenjan (2001:598) define a PPP as “cooperation of some sort of durability between 




risk, cost and resources which are connected with these products”.  PPPs rose to prominence in the 
1980s as a strategy to raise capital without increasing public sector debt to fund infrastructure 
development.  During this era, governments were pressured to reduce spending and pair up with the 
private sector, which was assumed more efficient and better at cost management capabilities than 
the public sector (Gideon and Unterhalter, 2007).  In the next decade, Mirafrtab (2004) asserts that 
the donor community promoted the agenda in the global South; at a time of relentless pressure for 
economic structural adjustment programmes and reduction of government spending in provision of 
public goods.  It is therefore not surprising that critics saw this as ‘welfare pluralism’ and the shift to 
private funding that allowed multinational corporates a foothold in public service provision services 
(Birch & Siemiatycki, 2016; Standing, 2007).  (Gideon and Unterhalter, 2017) frame this as 
‘financialisation of the means of social reproduction in sectors such as health and education” which 
shapes policy direction towards profit motives for multinational corporates without an active 
consideration of promoting equity and social inclusion.  Consequently, there are arguments that the 
evidence for PPP benefits claims is not overwhelming, especially concerning poverty and inequality 
reduction (Romero, 2015; Trebilcock & Rosenstock, 2015; UNDESA, 2016).  Some of these arguments 
relate to the “draining the swamp” programmes of Margaret Thatcher in the UK where between 1987 
and 2006 the UK had signed 590 PPPs (Ball et al, 2002). 
 
However, PPPs have been identified as key financing vehicles for Sustainable Development Goals 
(SDGs).  SDG 17 focuses on the government-civil society–private sector partnerships and argues that 
they are ‘inclusive partnerships built upon principles and values, a shared vision, and shared goals that 
place people and the planet at the centre, are needed at the global, regional, national and local level.’ 
(UN, 2015; Gideon and Unterhalter, 2017). Literature shows that the bulk of PPPs have covered 
infrastructure development; roads, water reticulation, rail, energy, telecommunications and the 
general built environment. The various types for PPPs include the following: 
 
Table 1: Seven types of PPPs common in infrastructure projects 
Type of PPP Mechanism of the scheme 
Build-and-Transfer scheme (BT) Private sector sources funds, build infrastructure 
and hands over to the public sector.  The public 
sector pays the private sector agreed principal 
and interest. 
Build-Operate-and-Transfer Scheme (BOT) Private sector funds and builds infrastructure, 
maintains the infrastructure.  It recoups the 
costs through agreed charges (rates, rental or 
user fees) for the infrastructure.  On agreed 
dates, the infrastructure is transferred to the 
public sector. 
Build-own-operate-and-transfer scheme (BOOT) Private sector funds, builds, owns, operates, and 
then at the set time transfers the infrastructure 
to the public sector.  Costs are recovered 
including returns usually with minimal public 
sector interference. 
Build-lease-and-transfer (BLT) Private sector funds and constructs the 
infrastructure and on completion leases it to the 
public sector in order to recoup costs.  At the set 
time, the public sector stops paying lease and 
assumes ownership. 
Build-transfer-and operate (BTO) The private sector builds the infrastructure and 
transfers to the public sector.  The private sector 




of the public sector and the proceeds are shared 
as per set agreement. 
Rehabilitate-operate and transfer (ROT) Dilapidated infrastructure is handed over to the 
private sector to be refurbished, maintained and 
reconditioned.  The private sector operates the 
infrastructure for a set time to recoup costs 
incurred in refurbishing the infrastructure. 
Lease, develop and operate (LDO) The private sector leases an existing facility, 
restores or modernises it.  Thereafter the private 
sector operates the infrastructure for a set time 
to recoup costs and then transfers the 
infrastructure to the public sector.  
Source: Dube and Chigumira (2010) 
 
The building blocks of PPPs essentially involve the following dimensions; Finance, Design, Build, 
Operate, Maintain, and Deliver (Abuzaineh et al, 2018) and the combinations of PPPs in Table 1 and 
others not mentioned in this document emanate from a combination of these dimensions. Skelcher 
(2005) broadly groups PPPs into five classes: Strategic Partnering; Joint Ventures and Design-Build-
Finance-Operate (DBFO); Contracting-Out and Competitive Tendering; Public Leverage; and 
Franchising.  We do not delve into the mechanics of how these PPP operate or are organised in this 
paper.  However, our literature review shows that the major focus of PPPs is their utility as financing 
mechanisms and risk, resource and benefit-sharing vehicles between governments and the private 
sector (Walwyn and Nkolele, 2018), hence the prevalence of civil engineering types of PPPs compared 
to health-complex types of PPPs that we focus on in this study. Unsurprisingly, the African 
Development Bank has been a major promoter of PPPs and serving as ‘‘an important backer of future 
PPPs” to boost investor confidence in the feasibility of PPPs on the African continent (ZEPARU, 2016).  
Generally, there are challenges in using the PPP approach in a number of African countries because of 
six key issues: non-conducive legal, regulatory and policy frameworks; unpalatable risk, poor 
perception of country risk; small market size; absence of deep financial markets; limited power in 
global trade and investment; as well as lack of skills to competently manage PPPs (ibid).  
 
A study of public-private interactions in the health sector in South Africa found that successful private-
sector involvement in technological and organizational innovations will require upgrading the skills 
and capacities of public-sector actors in procurement, contracting and performance management 
(Kula and Fryatt, 2014). New forums for stakeholder participation will also need to be created in order 
to include networks of policy makers, academics, care providers and civil-society groups capable of 
reviewing and evaluating PPPs and collaborating on learning and innovation (Kula and Fryatt, 2014). 
Roehrich et al. (2014) reviewed the literature on PPPs in health service provision and innovation and 
identified several risks of PPPs including: inappropriateness of certain PPP configurations, higher 
capital costs, stifling of innovation, limited competition, high transaction costs, misallocation of risks. 
However, there is still a lack of evidence on the impacts of PPPs and the factors contributing to success 
of failure (Roehrich et al., 2014), a gap among others which this study intends to contribute towards 
filling. Overall, there is need to understand the political economy of the health-industry complex, 
recognising the political and context-dependent nature of investments and interventions in these 
complexes and how these investments are influenced by wider socio-cultural, political-economic and 
scientific and technological contexts. 
 
 





Our original idea of the health-industry complex covered the relationship between pharmaceutical 
industry and the public health sector and the synergistic relationships that can be capitalised for 
innovation, industry development and health security simultaneously. In this paper, we are cognisant 
of the arguments surrounding PPPs, and we focus on the positive that they can deliver in clearly 
difficult circumstances where solely public or private investment may not yield much when the funding 
magnitude, risks inherent and the gestation as well as policy terrain are taken into consideration. 




Figure 1: Conceptual framework for integration of PPPs in innovation and service delivery for the 
health sector. 
 
Using this conceptual framework, the five case studies presented in this paper consider situations 
where ‘market failure’ can be overcome through PPPs in the health-industry complex focusing on the 
innovation pathways constituting the healthcare value chain.  
 
For the purpose of our study on applicability of PPPs in the health-industry complex, we split the 
innovation pathway into the following stages: research and innovation generation; innovation and 
technology development; translation and commercialisation; infrastructure design and development 
and finally; healthcare services delivery.  We desisted from using a linear depiction to avoid the 
impression that this is a linear process, as we wanted to project the iterative nature of the interaction 
of the various stages.  In this regard, we felt the wheel and hub presentation in Figure 1 above 
illustrates how PPPs can be used to strengthen the various spokes constituting the innovation 
pathways surrounding provision of healthcare embodied in the built environment and supporting 
medical health technologies and the clinical and management skills required to operate health 
institutions and allied industries.  Thus figure 1 should be read and understood in conjunction with 
Table 2 which shows the particular stages and activities or actions or funding streams necessary to 





Table 2.  Range of Health-related PPPs in a health-industry complex promoting innovation and social 
inclusion 
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Development 
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Source: Authors from interviews, literature review and AfDB (2017) 
 
Under the research and innovation generation we cover four key functions of training in technical 
skills, post graduate training and skills development, provision of research grants and innovation 
challenge funds.  This stage covers basic and applied research which leads to the second stage of 
innovation generation and technology development (Table 2).  Innovation acceleration and innovation 
incubation constitute the second spoke of the hub in our conceptual framework. The third spoke 
covers translation and commercialisation and the key activities covered in this phase are technology 
transfer and technology scale up with attendant focus on joint ventures and product development 
partnerships; as well as an innovation ecosystem supporting technology scale up, respectively.  The 
fourth spoke is the one most popular for traditional PPPs as it covers infrastructure design and 
development.  Most literature has examples of these types of PPPs that cover designing and 
construction of for examples hospitals and other built environment for healthcare delivery or the 
manufacturing sector.  The final spoke of the wheel is healthcare service delivery and this covers 
mostly technical skills deployment in both clinical and non-clinical activities as well as organisational 
management of infrastructure and institutions.  The last two stages of the framework are 
operationalised in the healthcare industry as shown in Figure 2 in the built environment interacting 
with preventative, curative and palliative healthcare and local pharmaceutical industries are linked to 
healthcare services through their provision of medical health technologies (therapies and medical 






Figure 2 Potential application areas in the built environment/infrastructure and the healthcare 
service delivery 
 
In our discussion of the case studies we use these frameworks as heuristic or sense making tools to 
understand what types of PPPs have been used in different countries and how effective they have 
been. 
 
4.0 Study rationale and methodology 
 
To date, policy and practice interventions have taken a silo approach to health and industry, ignoring 
the positive reinforcement from a coherent industry-health linkage consideration (Mackintosh et al, 
2017).  The intention of the study informing this paper was to assess the dynamics of PPPs as a viable 
financing mechanism for investment in the pharmaceutical sector (drugs and vaccines) that leads to 
better social inclusion in health (medicines access, affordability and security) through the health and 
industrialisation complex. For us, the study was both an assessment of the utility of PPPs and an 
endeavour to contribute learning to the health-industry arena in the study countries and beyond. To 
these ends, the methodology adopted for this study was informed by the overall focus of the study 
which was to unpack how health and industrialisation in Southern Africa, in the context of public-
private partnerships (PPPs) will be able to address issues of "competitiveness and social inclusion" 
while supporting local pharmaceutical production interlinked with a mutually-supportive health-
industry complex that fosters economic and social development. The underlying premise is that by 
purposively bringing together public and private sectors to support health and industrialisation, and 
deploying appropriate science, technology and innovation (STI) tools, African countries can take a 
long-term perspective towards solving local health security, economic development and social 
inclusion challenges.  Achieving this entails investing in research and innovation skills, capabilities, 
resources (including financial and technological), knowledge, networks and evidence-based policy and 
practice design, implementation and refinement.  A structured consideration of the complementarity 
of integrating public and private capabilities in delivering the benefits of a local health and industry 
complex speaks to the developmental and social inclusion needs of Africa, buttressed by sustainable 
financing and overall strengthening of health systems.  
 
4.1 Objectives of the study  
The study methodology further drew from the following objectives as set out in the terms of 
reference, which were to; 
1. identify, analyze and share the subtle lessons behind the success or failure of health and 




production of drugs and vaccines with potential for health systems strengthening/financing 
that leads to better social inclusion in terms of local health security, while at the same time 
exposing the challenges that the partnerships faced or currently face. 
2. identify and highlight key areas that foster social inclusion in local health security by focusing 
on (a) affordability – procurement and pricing of drugs and vaccines (b) access – distribution 
and supply chain management, and (c) promoting good manufacturing practice (GMP) 
certification, standards improvement (Bolo et al, 2016) and for innovative and emerging 
technologies priming the system for proportionate and adaptive governance of innovative 
technologies [new technologies coming from for example synthetic biology] and instituting 
anticipatory governance mechanisms. 
3. (explore drivers of competitiveness – through which we will adopt and deploy the Bolo et al 
(2016) framework that splits this into (a) financing, upgrading and capacity utilisation, (b) 
research, innovation and skills development and (c) intellectual property rights and 
technology transfer 
4. identify incentives, policy and regulatory frameworks that have been introduced or modified 
to improve (a) business environments, and (b) promote investment [including foreign direct 
investment - FDI] in the local sector and trade 
5. map out the unique policies, processes, practices and related factors that may have led to the 
success or failure of public-private partnerships especially in the area of health 
6. tease out lessons/action guides for the science granting councils on how to catalyse, manage 
and enhance knowledge exchange between academia, public and private sectors. 
 
4.2 Key research questions and research process 
In order to meet the above objectives, the study specifically sought to address the following 
overarching research questions which formed the basis of data collection instruments for the study:  
• to what extent are PPPs prevalent in the health-industry complex, in terms of research & 
innovation, health system strengthening and as an innovative financing mechanism, and to 
what extent have they contributed to health social inclusion.   
• what are the peculiar contextual realities of PPPs in health-industry complexes in Africa that 
need to be considered and what lessons can be learnt from other regions?  
• how can governance, regulator, incentives and policy frameworks be made more anticipatory, 
adaptable and responsive for more effective operation of PPPs in health-industry complexes, 
especially for emerging innovative medical health technologies? and  
• what metrics are required for effective monitoring, learning and evaluation of the role of PPPs 
in health system strengthening and financing?  
 
Across the different research questions and objectives, we also analysed the role of government as an 
investor in, regulator and facilitator of health-industry complexes and the wider political economy. 





Fig 3: HISA project research process 
This research adopted a case study approach, with the countries, their health and industrial sectors 
and specific programmes, companies or organisations serving as multiple case studies for careful 
analysis of the key areas of focus for the evaluation. As shown in Fig 3, data for this study was gathered 
using a number of complementary methods namely, document reviews, emailed questionnaires and 
interviews with some key respondents. Desk reviews were conducted against an evaluation checklist 
based on the evaluation purpose, objectives and key questions, while interviews were conducted 
using emailed questionnaires and/or semi-structured interview guides for different respondent 
categories (Annex 1) to ensure that the questions posed in the study purpose were covered in a 
complete and consistent manner. The research team also kept running notes of any other relevant 
points made by the various stakeholders during discussions or observations they made that were 
relevant to the study. Using the case study approach was best suited for this type of study for the deep 
and close in-situ investigation that we were able to obtain. Interviewees were free not to respond to 
any questions they felt uncomfortable with, and where feasible and desirable, anonymity was 
preserved. In total, we interviewed 40 key respondents, an average of 8 per country, these being 
drawn from the pharmaceutical industry, ministries of health & industry, health practitioners, civil 
society, academia and regional organisations. We also reviewed more than 50 key academic, policy 
and industry documents and closely studied more than 10 PPP cases across the five countries. The 
case studies, primary and secondary data form the basis for compilation of this commissioned paper, 
journal articles and a policy brief to be published.  
 
5.0 Study Findings  
 
5.1 Zimbabwe 
Zimbabwe attained independence in 1980 and just as South Africa inherited a nation with huge social 
and economic inequalities that manifested in unequal access to social services and infrastructure that 
supported health security.  The new government, as result, allocated resources to social development 
however, with the advent of the economic structural adjustment programmes in 1993 and subsequent 
land invasions in the early 2000s and political challenges; the country is currently facing severe 
economic and social challenges, more so in healthcare provision.  Historically health provision was 
characterised by exclusion policies that allocated the bulk of resources to the white community.  Less 
resources were allocated to the black community critical for industry and commerce in the urban 
setting; hence the unequal distribution at independence of government healthcare infrastructure in 
urban and peri-urban centres, compared to rural areas where the population was covered by the 





































































































































development of health infrastructure was driven by the racialist policies of the era.  A respondent 
highlighted how the Salisbury General hospital located at what is now Parirenyatwa General Hospital 
catered for the blacks and white through separate systems.  During the federation era (Federation of 
Rhodesia and Nyasaland – modern day Zambia, Zimbabwe and Malawi) general hospitals for the black 
communities were constructed in Harare (Harare Hospital), Bulawayo (Mpilo Hospital), Lusaka, and 
Blantyre (Blantyre Hospital).  
At the same time and critical to the health-industry complex argument on the importance of co-
location of pharmaceutical industry and healthcare provision, the Central African Pharmaceutical 
Services (CAPS) was established in 1953, followed by DATLABs a subsidiary of Adcock Ingram in 1955 
and Pharmanova in the 1970s and Varichem and Plus 5 Pharmaceuticals in the 1980s and 2000s 
respectively.  As will be discussed later this co-location of industry and local healthcare provision was 
instrumental in rapid policy and practice intervention a key public-private initiative that led to local 
manufacture antiretroviral drugs to combat the HIV/AIDS pandemic.   
Zimbabwe has successfully completed formalised PPPs in the road, water and rail infrastructure space 
and one in the health space; Chitungizwa Hospital and Baines Imaging, (Table 1).  Zimbabwe is 
however peculiar because of the long term preponderance of “un-formalised”, at times transient and 
transactional public private partnerships in; Innovation and Technology Development, Translation and 
Commercialisation and Healthcare Services Delivery, which have involved local industry, the public 
health system, government in general, faith based organisation, international non-governmental 
organisations.  We will discuss this in five specific case studies of: formulation development and local 
manufacture of ARVs; the EU-local pharmaceutical industry drug manufacture and supply of essential 
medicines during the hyperinflationary era; Natpharm partnership with the pharmaceutical industry 
for local manufacture of essential drugs; Mission Hospitals as invisible PPPs, as described by Mhike 
and Makombe (2018); and the HIV/TB PPP that the Ministry of Health and Child Welfare is developing.   
What has driven PPPs in Zimbabwe?  
The main driver of policy shifts towards PPPs in Zimbabwe has been the incessant economic 
challenges. The primary PPP candidates have historically been education, health facilities, and power 
infrastructure and transport as well as water reticulation.  This was driven by a crumbling 
infrastructure caused by the economic challenges of the 1990s as well as the political issues emanating 
from the reform in the early 2000s.  The country has accumulated a huge infrastructure deficit which 
the World Bank (2011) estimated needs a minimum investment of $2 billion per annum.  The revenue 
collections have been inadequate to cover this infrastructure gap, and consequently specifically for 
the healthcare sector PPPs have been mooted as a possible solution.  Thus spurred by this scarcity 
programmes such as ZimAsset recognised PPPs as a possible financing mechanism for propelling 
economic development (GOZ, 2013).  Clinical and non-clinical services were affected by the economic 
downturn especially between 2008 and 2009 (Dube and Chigumira, 2010) however, during the 
Government of National Unity era there was improvement in services, which have since deteriorated 
to date. Key areas affected include infrastructure, clinical and non-clinical services, staffing and 
procurement of medicines and other consumables.   
Our research echoes earlier studies (ibid) that hospital plant, machinery and equipment is one of the 
causalities of the economic downturn, and the areas most affected include diagnosis and treatment 
for diseases such as renal failure and cancer.  Those who can afford are opting to seek medical 
attention in neighbouring South Africa or India. Thus similar to the 2008-9 era, the burden of care has 
shifted to the private health sector, and out of pocket, health expenditure has increased, as medical 




National policies of PPP 
Although PPPs projects were commissioned as far back as 1993, it took 5 years for the government 
consider a framework for PPPs.  It was only in 2004 that the first attempt to develop a PPP framework; 
Public Private Partnership in Zimbabwe Policy and Guidelines (2004) commenced (Dube and 
Chigumira, 2010).  Dube and Chigumira (2010) reported that the framework never materialised, 
although some modicum of PPP framework was instituted with an exemplar of BOOT through the 
Zimbabwe Investment Centres, which incentivises actors in a PPP with a 5-year tax moratorium, and 
reduced tax rates for the ensuing 5 years.  There was renewed interest during the GNU in developing 
a comprehensive framework for PPPs and one of the identified key requirements was the creation of 
a clear ‘policy and institutional framework for PPPs’ which would signal to the private sector that 
government would protect investments through legal structures and support PPPs through a 
supportive institutional setup.  The activities of the GNU led to development of the following 
document that would have developed policies and institutions to promote PPPs as a key contributor 
to infrastructural development: 
• Public Private Partnership Policy of 2010,  
• Public Private Partnership Guidelines 2010,  
• Public Private Partnerships: Legislative Review for Zimbabwe, 2010, 
• Institutional Framework, Public Private Partnerships, 2010 
 
However, to date these documents have not yet been adopted (Table 3 below).  PPPs commissioned 
to date have been mainly handled by the Ministry of Finance in conjunction with relevant line 
ministries with key legislative instruments being the Income Tax Act Chapter 23:06; Procurement Act 
of Zimbabwe, 1999; and recently the Joint Ventures Act (chapter 22:22) which classifies PPPs within 
joint ventures. 
Table 3: Key legislation, programmes and policies supporting PPPs in Zimbabwe 
Legislation or Policy Mechanism 
Income Tax Act Chapter 
23:06 
Incentivises BOOT PPPs.  5-year tax holiday plus 5 years reduced tax 
rate 
Short Term Emergency 
Recovery Programme 
(STERP) 
PPPs where private encouraged for areas such as air, rail, power 
generation, water and road infrastructure 
STERP II Upgrade or roads plus new infrastructure provision 
Procurement Act of 
Zimbabwe, 1999 
Provides definitions for Project Finance Initiative.  Section 49 of the 
Procurement Act [22:14] also deals with the application of the Act to 
BOOT or BOT contracts 
Joint Ventures Act [Chapter 
22:22] 
 
The Act classifies PPPs 
within joint ventures. 
12th of February 2016, - Joint Ventures Act [Chapter 22:22] 
gazetted. The Act came into force in May 27, 2016 after passage of 
Statutory Instrument 53 of 2016 to operationalise it.  Joint Venture 
Act also provides for the institutions: 
• Joint Venture Unit (The Unit) 
• Joint Venture Committee – Secretaries of Ministry of Finance; 
Industry and Commerce; Transport and Infrastructure 
Development; Energy and Power Development; Local Government; 
Economic Planning; representative from the Attorney General and 
the Director of the Unit [ZEPARU, 2016] 




Public Private Partnership 
Policy of 2010  
[documents prepared in 2010 but not yet adopted] 
Public Private Partnership 
Guidelines 2010  
[documents prepared in 2010 but not yet adopted] 
Public Private Partnerships: 
Legislative Review for 
Zimbabwe, 2010  
[documents prepared in 2010 but not yet adopted] 
Institutional Framework, 
Public Private Partnerships, 
2010  
[documents prepared in 2010 but not yet adopted] 
Source: 
Mutandwa and Zinyama (2015) argue that Zimbabwe is not ready to embrace PPPs because the key 
pre-condition that acts as an investment signal and assurance to the private sector is the presence of 
a structured legal and political framework, which the country lacks as described earlier. Consequently, 
the environment is not conducive because the institutional framework has not been set up to support 
long-term investment which carries numerous risks (credit, commercial, currency, regulatory, political 
and payment) for the private investor.  Given the current socio-economic and political volatility in 
Zimbabwe, it becomes difficult to attract capital from within and outside the country given the long 
gestation periods for most PPPs. Despite Mutandwa and Zinyama’s (2015) argument (they focus on 
PPPs in water), and without a supportive PPP policy and regulatory environment, at least 14 PPPs 
(Table 4) have been completed or are ongoing in Zimbabwe.  Suffice to say most of the PPPs are in the 
transport and water sector with only a single PPP falling under the health sector - the Chitungwiza – 
Baines Imaging case study, which was discussed in-depth in the AfDB (2017) Developing coordinated 
public-private partnerships and systems for financing health in Africa: Experiences from Africa and 
India report5. 
Successful PPPs in Zimbabwe 
Table 4:  PPPs completed or ongoing in Zimbabwe in the transport, water, property and health 
sectors. 
Sector and type 
PPP 
Facility Year Completed 
Transport –Rail:  
BOT 
Beitbridge-Bulawayo Railway (BBR).  350km 
railway line from Bulawayo the border town 
of Beitbridge.  Reduced travel times from 
days to just 9hrs on this important 
commercial route. Critical for fuel transport 
from South Africa to southern parts of 
Zimbabwe 
Construction phase lasted 
18 months (record time) 
Transport -Toll 
Bridge: BOT  
 
 
New Limpopo Bridge (NLB) – awarded by 
the governments of Zimbabwe and South 
Africa.  * The first BOT project of this kind on 
the African continent 
Started in 1993 and 
completed 13 months later- 
Officially commissioned on 
24 November 1995. 
Transport- Road - 
BT 
Newlands By-Pass (NBP): Four-lane highway 








“Un-formalised PPPs” ARV 
formulation activities, 





Transport- Road - 
BT 
Plumtree-Harare-Mutare Road 
Rehabilitation of the road and construction 
of 9 toll gates 
Completed 
Transport – Road - 
BT 
Chiremba Road Development: Development 
of the road by a private investor. 
Completed 
Water – BOT Damafalls Development Water 
Augmentation Project: Bulk water supplies 
to Damafalls – a residential area 
25 Year project 
Water – BT Donnybrook Water Augmentation Project: 
Bulk water supply to Ruwa – a residential 
and industrial area towards the east of 
Harare 
Completed  
Water – BT Zimre Properties Water and Sewer 
Treatment Plant: Bulk water supply to Zimre 
a residential area 
Completed 
Water – BT ZB Water Augmentation Project: Bulk water 
supply to Ruwa 
Competed 
Water – BOT Muzhu Dam Rehabilitation: Bulk water 
supply in Chiredzi 
Completed 
Water – BOT Tongaat Hullets: Rehabilitation of Chiredzi 
Water Treatment Plant 
Completed 
Energy – BT ZESA/Zent: Manufacture of electricity 
metres 
Ongoing 
Property – BOT Sunway Housing Development: Servicing of 
residential stands in Harare 
Completed  
Health – ROT Chitungwiza General Hospital: 5-year PPP 
with Baines Imaging Group. Rehabilitation of 
theatre, renal, radiology, mortuary and 
pharmacy. 
2012-2017 
 Source: Dube and Chigumira (2010), ZEPARU (2016), AfDB (2017) 
Using the framework described above we turn to the specific Zimbabwean cases that demonstrate 
transient, at times transactional and “unformalised” PPPs in the health-industry complex as well as 
the public-third sector terrain that impact health security and improve social inclusion in health care. 























Case 1:  Government – Industry Partnership: Local manufacture of ARVs in Zimbabwe 
In the 1980s, Zimbabwe through HIV/AIDS faced a huge public health challenge that threatened to 
overwhelm the health system.  At that time, according to a local industry source, the government 
approached the local pharmaceutical sector and encouraged them to produce ARVs locally.  The local 
firms approached the patent holders for ARVs and although there was initial interest, the deals fell 
through.  Consequently, the government issued a compulsory licence to local firms on the back of 
pronouncement of a state of disaster for the pandemic.  The local firms engaged in formulation 
development and by 2002, they had started producing ARVs.  The table below shows how the legal 
and policy frameworks to support local production of ARVs emerged (Table 6) 
Table 6:  Legal and policy framework changes that supported local production of ARVs 
Date Legal or Policy Change Justification 
1999 • Introduction of the AIDS levy to raise funds 
to support HIV/AIDS programmes through 
the National Aids Council (NAC) 
• After dollarization in 2009, AIDS Levy annual 
revenues were approximately USD39 million 
per annum (Bhat et al, 2016) 
Although much has been 
written about the aids levy, 
most literature omits the fact 
that this was conversion or 
redirection of an existing 
drought levy scheme that had 
been set up to raise funds to 
addressed effects of drought 
in the country. 
 
The AIDS levy was a product of 
government’s inability to 
access Global Funding for the 
HIV/AIDS programme at that 
time6 
2002 • Patents Act of 1996 was amended to 
conform to provisions of TRIPS agreement.  
 
• Section 34 of Patents Act, Cap. 26.03, 
provided for compulsory licensing and 
Government use of drugs.  
 
• Minister could authorise use of patented 
invention by any Government department or 
third party for services of state; as explained 
by Section 35: Any authorisation by Minister 
under section 34 during a state of 
emergence shall include power to make, use, 
exercise and vend the invention for any 
purpose, which appears to the Minister 
necessary or expedient. 
Public Health Threat – 
Government incorporated 
TRIPS flexibilities into 
Zimbabwe's domestic 
legislation and promoted 




• Through the General Notice 240 of 2002 with 
Official gazette published on January 17, 
2003; a State of Emergence on HIV/AIDS 
This allowed the state to allow 
local manufacturers to locally 
produce patented medicines 
for HIV/AIDS, including ARVs 
 




from January 1, 2003 to December 31, 2005 
was proclaimed.  
• The intention was for government to use this 
option to improve access to ARVs for 
patients in the country 
8 April 2003 • The Minister of Justice authorized Varichem 
Pharmaceuticals (Pvt) Ltd to produce ARV or 
HIV/AIDS related drugs, and supply 75% of its 
production to State owned health 
institutions 
Local production would 
augment import of generic 
ARVs from RSA and India. 
Source: compiled from Banda (2013) with information from Osewe et al (2018) and interviews 
(2019) 
Whilst local formulation of ARVs was under process, the government tasked the local firms to procure 
ARVs from India and other countries (Figure 4 – green arrows).  When the local companies had re- 
formulated the ARVs and sought regulatory approval from the Medical Control Authority of Zimbabwe 




Figure 4: Public, private partners’ interaction to promote ARV manufacture technology transfer 












Production of Varivar/Lamuvidine commenced in July 2003 followed by Stalanev 
(Stavudine/Lamivudine/Nevirapine) in October 2003 and Zidovudine in March 2005 and Indinavir in 
2005 (Osewe, et al, 2008).  Osewe et al (2008) reported that capacity at that stage was 1.15 billion 
tablets and capsules and the programme benefitted from public health procurement and this saw 
prices of for example Varivar falling from USD 30-50 to about USD 15 per month (ibid). 
This case study illustrates what we are claiming as transient, transactional PPPs that do not involve 
contracts but are undergirded by the social contract of assuring health security and in this case, it 
meant aligning industrial policy, Intellectual Property Rights, health policy as well as finance policy.  
We argue that current discourses on PPPs in health miss these type of “un-formalised” PPP which are 
needed at certain instances to solve an intractable health challenge. 
Case 2:  Health-Industry Complex: EU – and NATPHARM procurement of essential medicines 
Table 7.  Suppliers contracted to provide medicines for the EU Expanded Programme of Health. 




Contract Value in Euros 
Varichem Pharmaceuticals (Pvt) Ltd 1,987,300 
CAPS Pharmaceuticals (Pvt) Ltd. 2,289,784 
PCD (Wholesale Importer) 1,202,702 
GHC (Importer) 1,585,464 
Mission Pharma (importer) 1,049,615 
SJV (Importer)    253,280 
Total 8,268,145 
Source: Banda (2013). 
The second transient, transactional type PPP that is scarcity induced that occurred in Zimbabwe during 
the hyperinflationary era and into the dollarization era is exemplified by an EU funded programme 
that contracted local firms for procure and produce medicines for the health system that was severely 
under-supplied with drugs (Table 7). Of the total amount of Euro 8.3 million, Euro 4.3 million was 
allocated to local drug manufacturers, and in interview the respondent highlighted the need to 
support the local manufacturing sector as one of the key components of that particular programme 
which was supported by DFID and EU.  This reflects the social contract nature of the PPP as illustrated 
in the NATPHARM example (Figure 5) where the Reserve Bank of Zimbabwe allocated foreign currency 
to the public health system drug procurement agency NATPHARM, which in turn paid in foreign 
currency directly to the supplier of raw-materials, and the local pharmaceutical firm used them to 
manufacture drugs and deliver to the procurement agency.  NATPHARM in turn supplied the drugs to 














Figure 5: Natpharm strategic procurement of raw materials for local drug production 
These two examples reinforce our argument about scarcity induced PPPs which are transactional and 
transient in nature, which have proved useful in unstable economic situations where traditional PPP 
which depend on traditional project financial appraisal would not be suitable.  As we shall argue later 
there are circumstances where these types of transactional and transient PPPs can play a role not only 
in social inclusion of marginalised populations but also support technological capabilities preservation 
by allowing firms to operate in challenging economic environments.  The knowledge exchange and 
flows are between the private sector, the public sector and the third sector exemplified by 
development agencies or international NGOs.  What was interesting though was interviewees did not 
view these as PPPs as they were not fulfilling ‘the traditional characteristics of popular PPPs’. 
Case 3: Mission Hospitals - invisible PPPs since colonial times 
Mhike and Makombe (2018) argue that Mission and State Hospitals have been invisible PPPs since 
colonial times and even after independence in 1980, they continued as PPPs, with Mission Hospitals 
playing a critical role in social inclusion and serving patients in rural areas.  Thus, from a social inclusion 
perspective, access to health and training of nurses and student doctors on attachment Mission 
Hospitals, State Hospitals, and the Ministry of Health have been “un-formalised” PPP which have been 
long-standing.  The government through budgetary support fund Mission Hospitals and it also covers 
the salaries for medical professionals in these institutions. 
 
 













Table 8: The number of healthcare facilities in Zimbabwe as at 2015 
Zimbabwe Healthcare Facilities 
Primary Care Facilities Referral Healthcare Facilities 
Clinics 1122 Central Hospitals 6 
Polyclinics 15 Provincial Hospitals 8 
Private Clinics 69 District Hospitals 44 
Mission Clinics 25 Mission Hospitals 62 
Council/Municipal Clinics/FHS 96 Rural Hospitals 62 
Rural Health Centres 307 Private Hospitals 32 
Total 1634 Total 214 
Grand Total 1848 
Source: ZSARA (2015) 
Mission Hospitals fall under the remit of the Zimbabwe Association of Church Hospitals (ZACH); the 
medical arm of all churches in the country.  ZACH was established in 1974 and currently has a 
membership of 130 hospitals and clinics7, contributing 68% health care delivery in rural Zimbabwe and 
35% nationally.  Reflecting the racialized health service delivery of colonial times, ZACH hospitals and 
clinics are characteristically located in remote difficult to access parts of the country and consequently 
their catchment covers socially excluded and poor communities.  The magnitude of their contribution 
to healthcare is reflected in 22 of the mission hospitals being designated as District Hospitals delivering 
training for Primary Care Nurses, Midwives and State Registered Nurses, which supports work force 
development for the health sector (Table 8).  In addition, Mission Hospitals work in conjunction with 
the Universities and Ministry of Health and Child Care by accepting medical students for training 
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7 http://www.zach.org.zw/about-zach/  
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Figure 6.  The healthcare facility set up and 4-tier referral system for urban and rural communities 
The National Health Strategy for Zimbabwe (2016-2020) acknowledges the role the private sector 
plays in funding and delivering healthcare. Echoing Mhike and Makombe (2018) the strategy 
document highlights that although mission hospitals have a long history of collaborating with 
government; the funding through grants in real terms has declined, implying they have had to source 
funding elsewhere.  In terms of partnering the private sector the strategy document reports that the 
greatest challenge is lack of “a defined public-private partnership framework within which to 
cooperate”.  The mission hospital as unofficial PPPs (Figure 6) were a key source of social inclusion 
and literature shows that they serve as channels of funding from the donor community targeting 
healthcare provision in marginalised and remote areas.  Table 9 illustrates how ZACH related clinics 
and hospitals have collaborated with various development partners in the provision of medicines, 
HIV/AIDS prevention programmes, antimicrobial resistance management programmes and other 
services.   





CDC/PEPFAR HIV&AIDS prevention, treatment, care services.  
Collection and utilization of surveillance data.  
Implementation of evidence based public 
health interventions within a network of 
church-related hospitals and clinics and 
immediate communities. 
CDC/ I-TECH Scaling up VMMC Services in Zimbabwe 
Global Fund/NAC- SASA HIV Programmes 
EPN/USAID/SAIPS Antimicrobial Resistance 
Brothers Brother’s Foundation (BBF) Equipment and Medicines 
HPIC Medicines 
Action Medeor Medicines 
Restore Vision Reading Glasses 
MOHCC  Annual grant to the secretariat, Government 
grants to all mission hospitals and clinics, 
Human resources, medicines, equipment and 
infrastructural development. 
 
Previous Partners Activity 
Catholic Relief Services (CRS) Nutrition Improvement Program 
DANIDA Office Equipment and Hospital Supplies 
European Commission Training of primary counsellors (VHSSP) 
EED Institutional Funding and Vehicles 
ICCO Institutional Funding 
GTZ/Royal Netherlands Embassy Rehabilitation of Water Supply and Sanitation 
OAK Foundation Water and Sanitation Project 
Mild-May International/EU Improving the quality of life for children living 
with HIV and AIDS and OVCs through building 




support networks to care and support such 
children 
World Bank Strengthening the capacity of both the 
Secretariat and member institutions 
(Governance Training) 
Global Fund-HIV/TB/Malaria Capacity Building of hospitals and districts 
OXFAM Australia Community Home Based Care and Livelihoods 
(Empowering PLWHIV in livelihood) 
Source: ZACH Partners http://www.zach.org.zw/partners/ 
Case 4:  Private Ward at Parirenyatwa Hospital – a co-location PPP to retain health skills 
The most common PPP identified by all respondents in the health sector was the Parirenyatwa Private 
Ward Scheme that has run from pre-independence times. In this scheme designed to attract and retain 
specialists at the government hospital, a wing of wards designated as Private Wards.  Doctors refer 
patients from their surgeries and clinics to the Private Wards and they are treated in the referral 
hospital by their doctors and physicians, who in turn also treat patients admitted in the non-private 
section of the hospital.  
This however is not an official PPP, but an arrangement that has been in place for a long time.  The 
doctors accept Medical Insurance and out of pocket payment for services.  In the case of medical 
insurance if there is a shortfall, the patient pays the doctor and the hospital. 
Key findings from the Zimbabwe 4 case studies and reflections on PPP literature 
One of the key findings in Zimbabwe are the social function of PPP in dealing with economic 
challenges, and as a result the types of PPPs identified are not in line with literature as they are 
transient, transaction based and serve a purpose in scarcity induced situations.  Thus, these PPPs show 
that they serve other socio-economic functions beyond those discussed in literature and practice.  This 
is however not surprising given that most of the literature tends to focus on PPPs in infrastructure or 
other management based activities and not on solving critical socio-economic challenging situations 
for both the manufacturing sector as well as healthcare delivery sectors.  We classify these as 
transient, transaction-based PPPs in addition to what Mhike and Makombe (2018) term invisible PPPs. 
Dube and Chigumira (2010) identified four key issues; financing, policy and institutional framework, 
risk analysis and expertise in PPPs. 
• Finance 
Finance capability is important – key funding schemes are debt and or equity and best availed through 
project finance.  The project should be self-securing hence; the project needs to be robust and capable 
of paying bank the debt.  Use of Special Purpose Vehicles is common in such ventures and the SPV is 
the contracting partner for all other players (UN ESCAP).  It is usually recommended that the SPV be 
constituted of the sponsors and they can also include government.  Availability of well-developed 
financial markets is one of the conditions conducive for PPPs. 
• Policy, legal and institutional framework 
Policy frameworks are important for clarifying how the PPPs function and process pathways to 
approval and operations, and their absence in Zimbabwe has been identified as one of the key issues 
that has held back PPPs.  Legislation is reported in literature as acting as both insurance and assurance 
to investors confirming that the government will honour its obligations.   The absence of a legal 




currently has no dedicated PPP law, and as discussed earlier the PPP guidelines developed in 2004 are 
still under review and the PPP policy of 2010 has to date not been adopted. Zinyama and Nhema 
(2015) argue that Zimbabwe should simplify rules, regulations and procedures to remove bottle-necks 
for smooth functionality of the government - achievable through policy consistency and predictability 
to boost confidence in investors. 
Zimbabwe unlike South Africa does not have a dedicated PPP unit, and to date all PPPs are 




5.2 South Africa 
South Africa attained independence in 1994 and inherited a society that had institutionalised racism, 
characterised by huge inequities spanning citizen rights, wealth and skills and especially in terms of 
access to social services Gqoli (2005).  It is within this context that PPPs have been actively used in 
South Africa as a mechanism to address this historical inequity urgently by rapidly progressing towards 
equitable social service provision supported by infrastructure development targeting marginalised 
communities through the three government levels; national, provincial and local.  In 1994 the country 
was divided into nine provinces; Gauteng, KwaZulu-Natal, Mpumalanga, Eastern Cape, Northern Cape, 
Free State, North West, Limpopo, and Western Cape; each with varying population densities.   
In the latest midyear population estimates, Gauteng constitutes 25.8% (1.2 million) of the population, 
KwaZulu-Natal coming second at 19.2% (11.3 million), and the province with the smallest population 
was Northern Cape with 2.2% (1.26 million) of the population (Stats SA, 2019). Given these 
demographics it is not surprising that South Africa stands out in this study as the nation that has 
achieved more by using PPPs in health spanning infrastructure development, hospital management 
and joint ventures (see Table 11).  Consequently, the South African government has considerable 
experience in health public-private interactions, however, Kula and Fryatt (2014) assert that more 
collaborations could result in improvement in procurement, contracting and performance 
management.   Gqoli (2005) chronicles the genesis of policies related to PPPs; beginning with the 1997 
decentralisation of budgeting by government, which led to three-year rolling spending plans and 7-
year forecasts.  This was followed by enactment of the 1999 Public Finance Management Act and later 
in 2000 the Treasury Regulation for PPPs which led to establishment of the PPP unit and finally the 
Municipal Finance Management Act of 2003 (see Table 9).  In terms of the specific PPPs in health the 
AfDB (2017) report provides a more in-depth discussion detailing the specifics of the various types of 
health PPPs (see Table 11 for examples).  In this study, we describe these PPPs in brief to give broader 
contexts of how they have been deployed in South Africa, however we select the BIOVAC Institute as 
the case study to draw lessons learnt on the role of PPPs in the health-industry complex that can 
impact and shape health systems strengthening. 
What has driven PPPs in South Africa?  
Abuzaineh et al (2018) highlight five key drivers of PPPs in healthcare: inadequate or old infrastructure 
in need of refurbishment or new infrastructure; financial constraints for governments to fund new 
infrastructure development or refurbishment; scarcity of management capabilities to improve health 
outcomes; better supply chain management supported by efficient procurement systems; and the 
need for specialist services or skills.  The South African government recognised that in order to rapidly 
address the social imbalances that apartheid brought, PPPs were a viable option to deliver better 
health to especially marginalised communities. Consequently, the South African government since the 
early 2000s has successfully commissioned PPPs in health (see Table 10). 
National policies of PPP in South Africa 
The South African PPP Manual (National Treasury, nd) describes a PPP as “a contract between a public-
sector institution and a private party, in which the private party assumes substantial financial, 
technical and operational risk in the design, financing, building and operation of a project”. All PPPs 
are governed under Treasury Regulation 16, and other bodies of legislation used to govern and 
regulate PPPs in the country include the Constitution, Municipal Finance Management Act 2003 and 
the Municipal Systems Act 2003 and the Public Finance Management Act 1999.  Given the 




Africa devised the black economic empowerment (BEE) policies to address the historical imbalances, 
thus the PPP BEE policy is structured in a way that encourages broad-based and sustainable outcomes. 
The strategy is two pronged; institutions need to adhere to BEE policy in PPPs by selecting a 
transaction advisor and secondly in the selection of the private partner in the PPP (Gqoli, 2005).  The 
BEE policy in PPPs has a scorecard which focuses on equity, management and employment, 
subcontracting and the local socio-economic impact (ibid). 
The policies in health PPPs date back to 1994 when the South African constitution enshrined health 
as a human right and the government embarked on redressing the apartheid imbalance. In 1996 the 
state adopted privatisation policies and in 1997 cabinet approved the establishment of the PPP Inter-
Departmental Task Team (IDTT) to develop a package of policy, legislative and institutional reforms 
that would support PPPs (see Table 10).  This was followed by the adoption of a PPP strategic 
framework in 1999 and Public Finance Act no. 1 and in 2000 the treasury regulations for PPPs were 
issued which led to the establishment of the National Treasury PPP unit.  In 2001 the Treasury Manual 
for PPPS was published and in 2003 the Municipal Finance Management Act no. 56 of 2003 was 
enacted and this made provision for consistent financial accountability for local authorities and also 
provided municipal PPPs and treasury view on feasibility. 
Table 10:  PPP related policies and their key drivers or rationale in South Africa. 
Year Key drivers/rationale PPP and related policy actions 
1994 Apartheid ends and the new 
government embarks on political 
and socio-economic 
transformation 
Adoption of the new South African constitution, 
which enshrined health as a human right 
1996 Privatisation policies start to be 
implemented 
Official adoption of privatisation by the state 
1997 Cabinet approved a PPP Inter-
Departmental Task Team (IDTT) 
to develop a package of policy, 
legislative and institutional 
reforms that would support PPPs 
PPP IDTT formed 
1999  Adoption of PPP strategic framework 
Public Finance Management Act 
no. 1 of 1999. 
Reduced micro budget management by Treasury 
 
National and provincial departments 
accountable for value-for-money decisions and 
delivery 
 
National Treasury maintains tight budget 
oversight and guidance 
2000 Treasury regulations for PPPs National Treasury PPP Unit formed - consisting 
of five professional staff drawn from the public 
and private sectors - technical assistance from 
the United States Agency for International 
Development (USAid), the Deutsche Gesellschaft 
für Internationale Zusammernarbeit (GIZ) 
(German Aid) and the Department for 




2001  Treasury Manual on PPPs published to serve as a 
key document for establishing PPPs in South 
Africa 
2003 Municipal Finance Management 
Act no. 56 of 2003. 
Consistent financial accountability system for 
local authorities 
 
Provides for municipal PPPs and Treasury view 
on feasibility 
 
Source: Compiled from Ngwamba (2014), Gqoli (2005) and Arimoro (2018) 
The treasury manual outlines the steps that need to be taken to execute a PPP in South Africa (see 
Figure 7).  The project preparation stage is composed of three phases; with phase 1 covering 
project inception and phase 2 covering the feasibility study and the third phase focusing on 
procurement.  The last step is the project term also covering three phases of development, 
delivery and exit.  Figure 8 shows the various types of PPPs as laid out in the Treasury Manual, 
ranging from PPP agreement, Financing Agreement, Direct Agreement, Operations Sub-
contracting, Shareholders Agreement as well as Construction sub-contract 
Figure 7:  The South African PPP Project Cycle showing pathway to approval of a PPP 





Figure 8:  The various forms of PPPs as enunciated in the South African PPP Manual 
 
Source: National Treasury (nd.) South African PPP Manual 
Successful Health PPPs in South Africa 
Since the early 2000s, South Africa has initiated at least 11 PPPs in health (see Table 10 for examples), 
of which 8 have been completed.  Seven of these PPPs were in five provinces with one at national 
level.  The projects covered by the PPPs in health span asset financing mechanism, co-location, 
facilities management, renal care services, and concessions (AfDB, 2017).  As at 2017, there were two 
PPPs under review; Tri-generation Chris Hani Baragwanath Hospital and Northern Cape renal dialysis.  
The Tri-generation Chris Hani Baragwanath Hospital PPP involved the installation of the tri-Generation 
plant at the hospital to reduce dependence on the national grid.  The Northern Cape renal dialysis PPP 
involved Kimberley, Upington and Springbok renal dialysis units’ refurbishments, staffing and 
equipping (RSA Budget Review, 2018).  For a more granular discussion of the health PPPs in South 
Africa (table 11) – the AfDB (2017) report covers this.   
Table 11:  Successful health PPPs implemented in South Africa 
Type of PPP Description Government 
Institution 
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Source: AfDB (2017), RSA Budget Review (2018) 
An analysis of the health PPPs in South Africa according to our conceptual framework span different 
aspects of the innovation continuum (See Table 12).  Hospital infrastructure, as well as clinical and non-
clinical services provision span infrastructure development (the built environment) and last mile health 
delivery services, whereas the Expanded Programme for Immunisation (EPI) vaccine procurement plays 
a dual role of healthcare delivery as well as a signal to investors that if vaccines are produced there is a 
market for them, however the procurement is still subject to tender procedures.  Development, 
reformulation, local manufacture and packaging activities on the other hand span research and 
innovation generation, innovation and technology development as well as translation and 
commercialisation.  We will discuss this in more detail in the Biovac Institute case study below. 
PPPs are not prevalent in the pharmaceutical manufacturing sector, especially so in the small molecules 
sector.  Although the PPP model in South Africa has worked for vaccines, in most cases it is the private 
model that dominates the sector.  We now turn to the Biovac case study in the next section to highlight 
what worked well, challenges faced, the innovations that have come out of this PPP and some of the 
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The BIOVAC Case Study - Historical vaccines and sera manufacturing capabilities 
The story of the Biovac Institute is intricately interwoven with the historical biological manufacturing 
capabilities of the South African government that pre-dates 1994, the resolve to keep vaccine 
technological capabilities, loss of some of these capabilities as state owned biologicals institutions 
were closed and how the PPP Biovac emerged from this era as a critical player in the health-industry 
complex.  Table 13 shows that the predecessor state owned institutions that date to the 1930s and 
1950s included the Johannesburg located State Vaccine Institute, and located in Johannesburg; the 
National Institute for Virology (NIV) and the South African Institute for Medical Research (SAIMR).  
These were three institutes publicly owned, connected and controlled by government. The 
respondents reported that the State Vaccine Institute produced BCG Vaccines, Smallpox Vaccines, 
Foetal calf serum and Human Growth Hormone whilst Rabies vaccines were at the time under 
development. The National Institute for Virology produced Yellow Fever Vaccine and Oral Polio 
Vaccine.  The Southern African Institute for Medical Research on the other hand manufactured DTP 
vaccines, cholera and typhoid vaccines and anti-sera for snake, scorpion and spider.  All these three 
institutes were closed by the early 2000s, except the State Vaccine Institute which became the Biovac 
Institute. 
Table 13:  Historical vaccines manufacturing capabilities in South Africa – pre-independence days 
Location Name of Entity Manufacturing Capabilities Current Status 
Cape Town 
 
State Vaccine Institute (SVI) • BCG Vaccines 
• Smallpox Vaccines 
• Rabies vaccine was in 
development 
• Foetal calf serum 
• Human Growth Hormone 
 
Closed 
Johannesburg National institute for 
Virology 
• Yellow Fever Vaccine 
• Oral Polio Vaccine 
 
Closed 
South African Institute for 
Medical Research (SAIMR) 
 
• DTP vaccine 
• Cholera and Typhoid 
vaccines 
• Snake anti-serum 





• Spider anti-serum 
The State Vaccine Institute in Cape Town is what later became the Biovac Institute and when it was 
established in 2003, it carried over some staff to the new entity.  The State Vaccine Institute (SVI) was 
a directorate within the department of health, and illustrates how the government directly invested 
in developing technological capabilities in local production of pharmaceuticals (biologicals) for its own 
consumption in the public health sector. 
The products manufactured at the SVI dating back to 1984 were BCG Vaccine; a percutaneous 
vaccine which was the only vaccine product sold commercially out of SVI the world.  The challenge 
however was the world was transitioning to intradermal vaccines which presented a technological and 
investment challenge for the SVI.  Transitioning to the new mode of vaccine delivery would have called 
for clinical trials and at that stage there was no commitment to invest in that.  The respondents 
highlighted that there were similar technological transitions for the other products in terms of 
production methods, quality assurance, ethical concerns and commercial viability.  Thus, in the late 
80s conversations of where to proceed were held with government department.  As discussed earlier 
the respondent reported that it became apparent that they could not continue as per usual because 
they needed to improve quality. The government in the late 1980s and 1990s and after consultation 
with WHO, UNIDO and others a decision was made that vaccine production could not continue.  They 
could either stop production or re-invest in production capabilities.  The critical questions that needed 
to be addressed according to the respondent was whether re-investment would be via a private 
venture, a PPP or the public sector. Early in the 1990s a decision was made to form a PPP, and this 
was carried through into the new democratic government. However, the respondent highlighted the 
fact that from conception to signing it took 10 years for the Biovac Institution involving three different 
rounds of RFPs (request for proposals). 
Biovac Institute ownership structure and reason for the PPP 
The Biovac Institute according to Walwyn and Nkolele (2018) was set up in 2003 as a strategic equity 
partnership between with the Biovac Consortium (Pty) Ltd and Government.  Biovac Consortium 
ownership structure included Biovac Holdings (62.5%), Heber Biotec (15%), VaxIntel (15%) and the 
Disability Employment Concern Trust (7.5%).  Biovac Consortium then formed a partnership with the 
government through the Department of Science and Technology.  The Biovac Consortium holds the 
controlling share of 52.5% whilst the government holds 47.5% of the shareholding (see Table 14 
below).  
Table 14:  Shareholding Structure of the Biovac Institute 
Biovac Consortium Shareholders 
Biovac Holdings  = 62.5%  
Heber Biotec = 15%  
VaxIntel = 15%  
Disability Employment Concern Trust =7.5% 
 
Biovac Consortium 
Led by Management  = 52.5% 
South African Government through the 
Department for Science and technology’s 









Source: Compiled from Walwyn and Nkolele (2018) and Morena Mokoane, CEO BIOVAC 
presentation at AVMI Conference Cape Town 2019. 
According to Walwyn and Nkolele (2018) this PPP was driven by strategic reason to maintain local 
vaccine security of supply via local manufacturing capabilities; as argued earlier based on the historical 
manufacturing capabilities of the South African state-owned institutes.  Our interviews also reinforced 
the assertion by Walwyn and Nkolele (2018), and the agreements involved a “Supply Agreement, 
Shareholders Agreement, the Subscription Agreement and the Strategic Equity Partner Undertakings” 
covering the 2004 to 2010 period, however these were renewed in 2016 (ibid). The mandate that was 
given to Biovac was to establish manufacturing capacity and supply uninterrupted EPI vaccines. 
Biovac technological capabilities 
Respondents reported that Biovac’s capabilities are in the Bacterial platform, fermentation and 
conjugate vaccines. In a presentation at the AVMI-TIBA workshop (African Vaccine Manufacturing 
Initiative – Tackling Infections to Benefit Africa), the Biovac CEO highlighted the products under 
development and on the market as well as the partnerships they are collaborating with (see Figure 8).  
In partnership with the Gates Foundation Biovac is currently developing the Group B Strep (GBS) 
vaccine which is undergoing clinical trials shortly, and undergoing formulation development they are 
working with Pfizer on PCV13.  On filling, they are collaborating with Sanofi on the hexavalent vaccine, 
whilst packaging Hexa, PCV, HepB and BCG in collaboration with Sanofi, Pfizer, Heber/CIGB and Aj 
Vaccines. For cold chain and distribution they are handling the following vaccines; Hexa, PCV, Rota, 
HPV, BCG, Measles, TT, Td, Flu and HepB working in collaboration with Sanofi, Pfizer, GSK, Biofarma, 
AJ Vaccines, Bionet, BioE, Seqirus  and CIGB. 
An analysis of the collaborations for Biovac as illustrated in Figure 9 shows that this health PPP is 
collaborating and co-innovating with leading pharmaceutical firms in the world, signifying embedding 
within global value chains for vaccines and activity in global vaccine innovation ecosystems.  In the 
interviews, the respondents pointed out the importance of these collaborations in terms of 
technological learning and technology transfer.  What is also apparent is that the further left one 
moves on the value chain in Figure 8, the more dominant philanthropic sources of funds become in 
supporting activities, whereas it is easier to strike commercial collaborations for filling, packaging and 
labelling and cold chain distribution.  The cold chain distribution is highly active because of Biovac’s 
role in procuring all EPI vaccines for South Africa and also for neighbouring countries such as Namibia 
and Botswana.  Biovac has enjoyed an exclusive agreement with the government to be the sole 
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Source: Morena Mokoane, CEO BIOVAC presentation at AVMI-TIBA workshop – Cape Town, June 
2019. 
Biovac has also developed a vaccine for Haemophilus influenza which it has licenced out to Japan and 
as a result they are earning royalties for that technology.  However, the respondents pointed out that 
it takes 12 to 15 years to place a vaccine on the market – hence the need for patient capital and 
assured market as an investment indicator. 
Biovac currently has two research and development laboratories, two sterile manufacturing suites, 
quality control laboratories and packaging and labelling suites with state of the art machinery (Figure 
10).  In terms of technological capabilities, they are well versed with bacterial conjugation and 
fermentation skills, as well as sterile filling and pre-filled syringes, and analytical capabilities spanning 
microbiology and chemistry.  Their local plant is cGMP certified by the South African regulator SAPRA 









Figure 10:  Facilities, processes and the partnerships that Biovac possesses 
 
Source: Morena Mokoane, CEO BIOVAC presentation at AVMI-TIBA workshop – Cape Town, June 
2019. 
Innovation ecosystems surrounding vaccine development and manufacture 
Biovac in South Africa closely works with the Chris Baragwanath hospital in Johannesburg where a 
group of clinician academics identify strains of bacteria for certain diseases and isolate the key types 
required to make a vaccine.  Thus, the health PPP is working with the public health system, as well as 
academics in local universities; and given the fact that there is a private partner in the PPP this 
illustrates a peculiar triple helix concept.  The status of PPP was reported to assist in accessing the 
Baragwanath hospital as well as the University collaborations.  Our respondents reported that in their 
particular case this has been promoted by the bioeconomy strategy for the country.  The bioeconomy 
strategy is run centrally through government via the Department of Science and Technology (DST).  
DST is the driver behind the bio-economy strategy and they close the circle by being both a broker 
and integrator linking up the PPP, local universities and hospitals, as well as other government 
departments/agencies.  Our respondents pointed out that DST for example usually suggest that they 
consider collaborating with local partners including CSIR (Council for Science and Industrial Research) 
before they resort to partnering external organisations.  The argument is that public funding is used 
to support basic and applied research at CSIR and actors such as Biovac concentrates on the 
development aspects on innovations and technologies.  We found this to be a particularly interesting 
example of how government funding of the riskier early stages of research/innovation through CSIR, 
helps to de-risk this stage and passes on to the developers of proofs of concept that may need scaling 




partners in all situation.  We found this strategic thrust to support local creation of innovation 
ecosystems a key lesson that other potential PPPs in the health could learn from.   
However, our study revealed that the academia – industry collaborations can be problematic.  The 
issues centre on challenges with scalability and transitioning technologies t industrial manufacturing 
and at scale.  The academia-industry conceptualisation and understanding of processes, practicalities, 
and end goals may not always be aligned.  The respondents argued that for academia the drive may 
be publications after success for example in model animals, whereas for industry the end goal is 
reproducibility and ability to scale up and manufacture at scale.  The other challenges in establishing 
the local innovation ecosystem is driven by lack of GLP (Good Laboratory Practice) certified partners.  
Consequently, it becomes difficult to carry out toxicology studies because the GLP certified 
infrastructure does not yet exist.   There are rational reasons why this is so; the market is not big 
enough at this stage to invest in GLP certified toxicology facilities.  Consequently, the facilities that are 
available cater for non-clinical pre-toxicology work. 
International partnerships and collaborations 
Biovac collaborates and partner with organisation in the developed and developing world (Figure 10).  
In the developing countries, they collaborate with Biofarma in Indonesia, Heber in Cuba, Bionet in 
Thailand, Sinovac in China, SII as well as BioE – both in India. In the developed countries Biovac 
collaborates with Sanofi, Pfizer and PATH.  These international collaborations indicate the global 
nature of innovations in vaccines and Biovac reports that they work with experts to solve particular 
issues for particular technologies they would be developing.  These partnerships and collaborations 
indicate that at this juncture Biovac seems to be navigating the collaboration-competition dilemma in 
a way that is advantageous to them, perhaps because historically they have been the preferred 
procurement agent for government for EPI vaccines.  However recently there was agitation in the 
sector when the government gave indications that vaccine procurement may be subject to open 
tender and there would be no preferred status for Biovac, and the press in South Africa produced 
reports indicating the risk of collapsing a company that was growing and contributing to technological 
development in the country.  At the time of writing this issue has not yet been resolved. 
The international collaborations also highlight that for PPPs it is not only sufficient to form a PPP with 
government, especially if you operate in a high-tech area; knowing who to collaborate with, crafting 
the collaboration agreement and acquiring the necessary technological learning through technology 
transfer are skills that need to be acquired.  
The philanthropic funding for research and development 
As described earlier Biovac is involved in research and development for the GBS vaccine with funding 
from the Gates Foundation.  The ultimate goal is for Biovac to locally produce the vaccine API (active 
pharmaceutical ingredient).  This is an example of a PPP- Philanthropic organisation collaboration for 
the purpose of developing a technology within an African country and whose application and reach 
can be global. The Gates Foundation funded research and development phases to manufacturing for 
clinical trials phase 1.  The clinical trials are being run by a CRO (Clinical Research Organisation) and 
again illustrates a PPP-Philanthropic Organisation – CRO (Private sector) collaboration.  These 
collaborations are testament to the complexity of partnerships that are required to bring a therapy to 
market, and the management agreements required at various stages.    If Biovac is successful there is 
a possibility of proceeding with the clinical trial and market authorisation, however the challenge will 






One of the issues brought out in the interviews was the complexity of regulating biologicals in African 
countries.  Whilst many actors in policy and industry sectors argue that these skills are scarce, our 
respondents at Biovac contended otherwise; arguing that in international fora experienced regulators 
who interact with African regulators commend them for their expertise and as such these skills are on 
the continent albeit they are pockets of excellence which are not prevalent across different countries. 
South Africa for example because of its history of vaccine and broadly biologicals manufacture dating 
to the 1930s and 50s has these skills and the local regulatory agency has the capacity to certify local 
manufacturing sites.  Our respondents also pointed to the presence of the African Vaccine Regulatory 
Forum (AVAREF) as evidence of the presence of these skills on the continent, and even wondered why 
AVAREF cannot become the continental regulator for vaccines.  AVAREF is composed of 34 African 
countries with quality control laboratories in place, 40 countries with medical products regulation in 
place and 21 countries with full time regulatory personnel assessing quality and pre-clinical data8 
However, there was a recognition that the African Union through the African Union Development 
Agency (AUDA)-NEPAD’s AMRH programme and the journey towards the Africa Medical Agency are 
efforts to solve the continental regulatory needs. 
How can regulation and incentives be structured in a way that supports PPPs 
Our study respondents identified the following as key issues pertaining to regulation and incentives 
that need to be addressed 
• Regulation should include robust discussions with manufacturers, academics, regulatory 
authorities and politicians when structuring the regulatory framework. 
• There are limited resources, capabilities and skills and they need to be managed astutely.  
Chatham house rules and frank discussion on what needs to be prioritised and clear roles and 
responsibilities on who is responsible for what is important for developing roadmaps for 
proportionate and adaptive governance regulatory systems. 
• Create a space for collaboration amongst different stakeholder. 
• There is also a need to avoid regulatory ratcheting – gold plating of standards; a familiar 
challenge when incumbents unnecessarily raise standards as a competitive tool. 
• There is a need to avoid multiple layers of regulatory oversight – mutual recognition of 
regulatory approval can help reduce regulatory costs to manufacturers. 
 
Procurement  
Walwyn and Nkolele (2018) point out that SA’s EPI vaccine procurements requires 46 million vaccine 
doses and as at 2015 the value was pegged at ZAR 1.5billion, and Biovac taps into this market as the 
procurer for the EPI vaccines for the state.  If this continues it is innovative procurement using public 
health financing as active industrial policy to support local industry development (Chataway et al, 
2016).  In the interviews, our respondents pointed to assured procurement as essential especially 
considering graduation from GAVI eligibility for many countries.  The second factor in terms of 
procurement that was highlighted was the need for medical insurance to acceptance biological 
therapies such as MAb (monoclonal antibodies) for treatment of cancer.  However, there is a dilemma 
that was posed as follows “if you are selling into the poor, how do you charge in a way that develops 
income that is ploughed back into development?”  Linked to this were two things that industrialists 
 




identified as worrisome.  With respect from the roll out of proper vaccine research and development 
and manufacturing on the continent it was pointed out that the region does not have a coherent 
vaccine plan or strategy, and secondly the supportive political, market, regulation environment does 
not yet exist.  Opportunities however exist for example in the snake anti sera in the Maghreb region 
– however, because players are not collaborating there is a risk of investing in the same areas whereas 
there could be an agreement on firms focusing on their areas of specialisation at this particular time 
in the vaccine sector. 
Gqoli (2005) attributes the success of PPPs in South Africa to a conducive political commitment; 
independent judiciary; clear PPP law, process, and standard terms; the existence of a PPP Unit in a 
strong National Treasury, very good projects, training, communication; strategic use of black 
economic empowerment, strong and deep financial markets supported by a competitive private 
sector.  However, there were still challenges faced with deal flow, public sector capacity, Municipal 
PPPs and some aspect of black economic empowerment 
5.3 Botswana 
Like many developing countries, Botswana faces challenges in the delivery of public services 
infrastructure including their maintenance and operational obligations. New infrastructure needs to 
be provided and existing infrastructure upgraded to deliver public services more effectively and 
extend access to services to a greater number of the population (Government of Botswana, 2019). 
Accordingly, the Government of Botswana is promoting the use of PPPs in developing and operating 
public infrastructure and related facilities. The Government of Botswana in 2000 adopted the 
Privatisation Policy aimed at enhancing the role of the private sector in the economy. This Policy 
provided for public-private partnership (PPP) as one of the methods of enabling private sector 
participation in the provision of public infrastructure and related services. Table 15 presents key 
legislation, programmes and policies supporting PPPs in Botswana. 
 
Table 15: Key legislation, programmes and policies supporting PPPs in Botswana 
Legislation or Policy Mechanism 
Adoption of the 
Privatisation Policy in 2000 
• Provides an optimal balance between the public and private 
sectors to achieve sustainable economic growth. 
• This Policy provided for public-private partnership (PPP) as one 
of the methods of enabling private sector participation in the 
provision of public infrastructure and related services. 
Adoption of the PPP Policy 
and Implementation 
Framework in 2009 
• Create a conducive environment to encourage and attract 
private sector investors to play a greater role in procuring and 
financing of infrastructure projects. 
Public Procurement and 
Asset Disposal Act 
• The legal and regulatory framework is embodied in the Public 
Procurement and Asset Disposal Act for central government 
projects and the Local Authorities Procurement and Asset 
Disposal Act for local authorities’ projects. 
Establishment of the PPP 
Unit in 2016 
• To coordinate, oversee and ensure successful implementation of 
the PPP Policy. 
• To provide technical assistance to sponsoring institutions 
throughout all the stages of the PPP process from project 
conceptualization to contract management, including 
procurement of the private sector. 
• Support the government entities in building capacity and skills 




advocacy, public awareness and sensitisation of the public and 
other stakeholders regarding the PPP Policy, processes and 
projects. 
Source: (Governement of Botswana, 2019) 
As shown in Table 15 above, the initiatives confirm the Government of Botswana’s commitment to 
the involvement of the private sector in financing and managing infrastructure projects. 
Public Private Partnerships form an integral component of the Government of Botswana’s overall 
strategy for provision of public services infrastructure across all sectors. To date there are two Projects 
which have been developed and are notable through PPP in Botswana namely; Ombudsman and Land 
Tribunal Office Accommodation Project and SADC Headquarters Office Accommodation Project 
(Tshombe and Molokwane, 2016). The first project was a ten-year concession for provision of office 
accommodation for the Office of the Ombudsman and Land Tribunal, inclusive of courtrooms, offices, 
auditorium, cafeteria and parking. Construction was completed within schedule (16 months). The 
project term expired and was handed over in 2017. The second project is still on-going and is a 17 year 
concession project for provision of office accommodation for SADC inclusive of offices, parking, 
resource centre and facilities management (cleaning, security and hard facility management). Farlam 
(2005) argued that in cases where partnerships have been able to best deliver desired outcomes in 
Botswana, thorough  planning,  good  communication, strong commitment from both parties  and  
effective monitoring,  regulation  and  enforcement  by government was prevalent.  This validates Fall 
et al. (2009)’s argument that successful PPPs have been part of well-designed sector reforms with 
clear policies and strict adherence to  governments  policy commitments. 
 
Under the Government of Botswana’s National Development Plan 11, development expenditure of 
over P100 billion was planned for the plan period 2017/18 – 2023/24 the bulk of which is to fund 
infrastructure projects in sectors such as water, energy, tourism, agriculture, education and health, 
priority being given to the maintenance of existing infrastructure. A pipeline of potential PPP projects 
in Botswana has been identified.  These projects will go through thorough assessment to determine 
whether they are suitable for implementation using the PPP method. The list is tabulated in Table 16 
below. 
 
Table 16: Recent PPPs in Botswana 
 
Ministry Project Description 




Construction of 4,000 housing units for 
secondary school teachers  
Ministry of Lands 
and Water 
Sanitation 
Glen Valley Waste Water 
Reuse Project 
 
Glen Valley wastewater treatment and reuse   
 






Water abstraction from Chobe-Zambezi river 





Economic Zones Common 
Facilities 
 
Construction/operation of common facilities 
for Economic Zones  
 
Ministry of Health 
and Wellness 
New Francistown District 
Hospital 
Construction of a new district hospital and a 
psychiatric department in Francistown 
Ministry of Health 
and Wellness 
 
Construction of Level 1 
primary hospitals 
 
Construction of Level 1 primary hospitals in 
Werda, Sebina, Tonota, Sehitwa, Botshabelo, 


























SSG Workshops and 
Houses 
Construction of SSG workshops and 150 staff 






Design, construction and maintenance of BPS 





Sepopa Prison Farm 
 
Construction of new prison comprising of 
Security Wing, Farm and staff houses at 





Construction of an 
Offender Rehabilitation 
Centre Lobatse  
Design, construction and maintenance of an 
offender rehabilitation centre in Lobatse  
 





Provision of integrated infrastructure services 









Development of meeting, conference and 







Three Dikgosi Monument Development of the “Three Dikgosi 




Serowe Magistrate Court 
 
Construction of Serowe Magistrate Court 
 
Source: (Government of Botswana, 2019) 
Health system challenges 
Botswana gained its independence from Britain in 1966, has a population of around 2 250 000 and has 
gained upper-middle income economic status with a gross domestic product (GDP) of US$ 17.38 billion 
in 2017 (CIA World Factbook, 2019). Geographically it is a landlocked country bordered by Zambia, 
Zimbabwe, Namibia and South Africa. The key socio-economic and health system indicators are 
summarised in Box 1.  Health services are based on a decentralised model, with health service delivery 
revolving around primary healthcare system comprised of 27 health districts which encompass 
(district hospitals, district clinics, health posts and mobile health clinics). This is augmented by an 
established network of 101 health clinics with inpatient facilities, 171 outpatient clinics and 338 health 





Box 1: Key socio-economic and health system indicators 
Source: https:www.cia.giv/library/publications/the-world-factbook/geos/bc.html 
 
The main health challenge in Botswana is posed by HIV/AIDS with 20 percent of the adult population 
infected with HIV, the fourth highest prevalence globally after South Africa, Lesotho and Swaziland 
(UNAIDS, 2017). Furthermore, structural drivers such as poverty, domestic violence, alcohol abuse, 
strong gender imbalances which disadvantage women have meant that HIV has been difficult to stem. 
Despite these impeding factors significant successes have been recorded in the fight against HIV 
particularly over the last decade through government-led programming efforts in which international 
partners have played central roles and structural support programmes have augmented efforts to 
improve education and employment opportunities (Loutfi et al., 2019).  
 
Table 17 presents a breakdown of the number of health facilities in Botswana. The main health care 
provider in the 27 administrative health districts is the Ministry of Health through a primary health 
network administered by primary and local authorities. The delivery of primary health services is 
through the central hospitals; Princess Marina in Gaborone and Nyagabwe in Francistown which also 
serve as referral centres for the remote rural areas and networks of clinics. Health services across the 
continuum of care (medical treatment, diagnostic investigations and drugs) are offered free to 
citizens, while foreigners pay subsidised costs.  This health system is lauded for its efficiency and reach 
and is viewed by policymakers in global health as an excellent exemplar of a successful healthcare 
model, with 95% of the population (85 percent of whom are rural living within an eight-kilometre 
radius of a health centre (WHO, 2009).    
 
















Botswana Healthcare Facilities 
Primary Care Facilities Referral Healthcare Facilities 
Government Clinics 277 Central Hospitals 3 
Private Clinics 167 District Hospitals 14 
Health Posts  338 Mission Hospitals 4 
Mobile Health Posts 844 Private Hospitals 10 
Total 1626 Total 31 
Grand Total 1657 
Total population (2018) 2,249,104 
Gross Domestic Product (GDP) US$ Billions (2017) 17, 38 
GDP per capita purchasing power parity (2017)                                                                                                                                          17, 000
Life expectancy at birth male/female (years, 2018) 61.8/68 




















HIV Vaccine research 
 
Botswana University of 
















(Botswana Ministry of 
Health, the US centre 
for disease control and 
the Global AIDS 
programme) 
Projects: Prevention of 
Mother to child 
transmission 
programme (PMTCT) 




CHAI and government 
pricing and negotiation of 
HIV, malaria and 
tuberculosis drugs 
ACHAP and Merck 
(donation of Crixivan and 
Stocrin) to initiate the 
national HIV treatment 
programme in the early 
2000 - 2009.  





Bill and Melinda Gates 
and Merck Foundation 
 
Projects: 
Building of Health 
Facilities 
HIV programme 






Hospital (Ramotswa – 
since 1933) 
Deborah Retief Memorial 
(Motshudi – since 1927),  
Kanye Adventist Hospital 
(Kanye – since 1922) 
Scottish Livingstone 
Hospital (Molepolole – 
since 1934) 
   CHAI in discount pricing 
and supply of diagnostics 
(mainly HIV, tuberculosis, 
malaria screening and 
treatment monitoring 
 
   Health systems 
strengthening  
CHAI as a technical 
implementing partner 









Research and Innovation: Botswana-Harvard AIDS Institute Partnership (BHP) 
Areas Covered by Partnership Partners Involved Primary Purpose of 
Partnership 
Collaborative research and 
training  
Private-Non-Profit 
Organisation, Academia and 
Government of Botswana 
Providing research and 
training in areas such as 
virology, molecular biology, 
immunology, genetics, 
epidemiology, as well as social 
and behavioural issues 
relevant to the AIDS epidemic 
in Botswana and southern 
Africa. 
 
Developed by authors with data from interviews and Botswanaharvardpartnership.org (2019) 
With a fully-outfitted research laboratory and training centre, the BHP is one of Africa’s leading 
scientific institutions. Besides the Botswana government, Harvard University and the University of 
Botswana, the BHP has other partners who include the DFID and Wellcome Trust from the UK, EDCTP 
and three universities from South Africa. This partnership, established in 1996, reflects growth and 
expansion designed to keep a partnership appropriate and relevant for the health, economic and 
societal challenges it seeks to develop.  At the governance level, the BHP was incorporated as a limited 
liability corporation under Botswana law in 2007 in order to become an autonomous legal, 
administrative, and financial institution. 
Manufacturing: Botswana Vaccine Institute 
Areas Covered by Partnership Partners Involved Primary Purpose of 
Partnership 
Research into and 
manufacture of vaccines for 
livestock 
Private Livestock Pharma 
Company (Merial – Sanofi) and 
Government of Botswana 
To research on, manufacture 
and supply livestock vaccines 
to ensure Botswana’s animals 
and animal products are free 
from diseases 
 
Developed by authors with data from bvi-bw.com and interviews (2019) 
• Accelerate 
uptake and 









BVI was established in 1979 as an autonomous and totally self-financing company wholly owned by 
the Government of Botswana (GoB), before later establishing and forging a strong technical 
cooperation with Merial (the animal health division of Sanofi). BVI’s original mandate was to produce 
vaccines to provide biological safeguards to ensure Botswana's livestock industry freedom against foot 
and mouth disease (FMD). The mandate has however since expanded to include other livestock 
vaccines including Foot and Mouth Disease vaccines-FMD, Contagious Bovine Pleuropneumonia 
Vaccine -CBPP, Peste des Petits Ruminants Vaccine-PPR, Anthrax vaccine and Quarter Evil/Blackquater 
vaccine. 
Pharmaceutical industry 
Currently there is no pharmaceutical production capacity in Botswana, mainly due to the small size of 
the market. There are, however, companies engaged in the importation and packaging of bulk drugs. 
Currently there are two pharmaceutical companies that are engaged in the importation of bulk drugs 
for packaging and distribution in the country, with plans to manufacture.  The Ministries of Health and 
Wellness & Trade and Industry recognise that the health sector of Botswana is awash with 
opportunities. The best prospects highlight the provision of construction, medical technology and 
surgical equipment, the supply of drugs and commodities, and supportive healthcare services for 
treatment of HIV/AIDS and related infections. Opportunities for partnership also exist in investment 
in the training of health personnel in the country, particularly in areas such as commodity planning 
and forecasting, as well as logistics and supply chain (www.moh.gov.bw & www.mti.gov.bw).  
A defining feature of the PPP model in Botswana is that despite the country bearing the fourth highest 
prevalence of HIV/AIDS Globally, Universal Health Coverage (UHC) goals are increasingly a tangible 
proposition, where the primary healthcare model for public health delivery is dominated by the public 
sector. At the same time, one useful indicator of health system improvement is the advancement 
towards the UNAIDS 90-90-90 targets, of which 91 percent of HIV positive people are aware of their 
status, 83 percent are on ARV treatment and 81 percent of those on treatment are virally suppressed 
(UNAIDS, 2019). Underpinning some of these successes are PPP arrangements directly or indirectly 
funded through the United States’ Presidential Emergency Fund For HIV/AIDS (PEPFAR), Bill and 
Melinda Gates Foundation or the Global Fund for HIV/AIDS, TB and Malaria.  
What is clearly evident is that PPPs in Botswana are visible in a range of configurations across health 
system strengthening, innovation and development, translation and commercialisation, infrastructure 
design and development and healthcare service provision. Whilst the remarkable strides in HIV have 
leveraged significantly on the PPP model to unlock the transformative capacity of private sector capital 
for broader health systems strengthening, it is important to discern vital lessons from this context. 
Among the key observations noted are the issues of ownership arrangements and governance which 
must be understood in greater detail. For example, whilst Botswana has successfully unleashed private 
finance, the partnerships between government, profit and non-profit sectors have tended to remain 
locked in silos (vertical or issue-focused). In that sense donor priorities have tended to be imposed 
over national priorities, even though the Botswana government has, uniquely, for an African country, 
maintained a long-term orientation on broader national health system and policy imperatives (Caines 
and Lush, 2004).  
 
Relatedly, there have been significant re-alignments and shifts in the composition and orientation of 
PPPs over the last 15 years reflecting emerging and current health system needs. For example, in the 
early 2000s, Botswana emerged as the first sub-Saharan country to implement the prevention of 
mother to child transmission (PMTCT) initiative through the BOTUSA project involving (Botswana 




community development. Following programme success, with significant reduction in vertical 
transmission of HIV, the ministry of health has taken this project over and integrated it into routine 
health system programme delivery. Latterly the focus has shifted to knowledge translation (BUMMI 
partnerships) and workforce development see table XXX, with ongoing research and development 
projects in HIV vaccine development (Botswana Harvard Partnership) (Druce et al., 2004).     
The PPP model in Botswana is unsurprisingly characterised by extreme heterogeneity:  for instance in 
health systems provision, on one end of the spectrum are drug access PPPs involving the provision, 
discount pricing on a range of drugs by international pharmaceutical companies such as Merck and 
GSK in the donation of and discounting arrangements of essential HIV drugs. For example, Merck 
donated Stoctrin® and Crixivan® which served as critical drivers in aiding the government to launch its 
antiretroviral (ARV) programme. At the other end of the spectrum are mission hospitals at the front-
end of care, these include Bamalethe Lutheran Hospital in Ramotswa, Scottish Livingstone Hospital in 
Molepolole (table XX). Noteworthily, these rely on the ministry of health for logistical support (supply 
chain and procurement) through the central medical stores for pharmaceutical and diagnostic 
supplies. Meanwhile, a vital feature of the PPP model in Botswana is the central medical stores which 
uses a robust IT based monitoring system for national drug and diagnostics supply and management. 
This system was developed in partnership with ACHAP which had a central role in securing and 
designing the storage space for ARV drugs (Caines and Lush, 2004). Bilateral support from the 
Merck/Gates partnership played a key role in the formation of ACHAP. Through the ACHAP 
arrangement bridging finance was provided to set HIV/AIDS programmes into motion. This raises a 
key point both empirically and conceptually regarding PPPs, that in some instances there is need to 
look beyond existing PPPs, to explore a wider range of both benefits and risks from those PPPs, 
including direct ones and collateral ones that arise from the catalytic role that the partnerships play. 
Continuous appraisal of partnerships is therefore important, to unpack their contributions and 







Public–private partnerships in Namibia are one feature of the growing economic landscape since 
independence was declared in 1990. However, Opawole (2018) argued that the adoption of PPPs is 
relatively new in Namibia, and empirical evidence relating to its application is scanty. This argument 
resonates with Kaiyamo et al. (2014) who pointed out that while PPPs are not new in Namibia, the 
pace at which they are implemented, particularly in the health sector leaves much to be desired. It 
was in this backdrop that subsequently that the Ministry of Health and Social Services (MoHSS) 
devised a PPP framework9 and invited the private sector to participate, but the response has been 
dismal (MoHSS, 2013).  
 
The World Bank supports Namibia in a Country Partnership Strategy (CPS) to achieve its Fourth 
National Development Plan that centralises development of state capacity and the private sector. The 
dedicated Development Bank of Namibia on the other hand provides funding for infrastructural 
projects completed by local or state-owned enterprises together with private companies, including 
direct loans for PPP enterprises (Commonwealth Governance, 2019). Table 19 below presents key 
legislation, programmes and policies supporting PPPs in Namibia. 
 
Table 19: Key legislation, programmes and policies supporting PPPs in Namibia 
Legislation or Policy Mechanism 
Namibia Public Private 
Partnership Policy (NPPPP) 
of 2012  
• Namibia has had a non-binding policy as its framework for PPPs 
since 2012 
Public Private Partnership 
Act, No. 4 of 2017 10 
 
• Was signed into law on 9 July 2017 
• Provides a legal framework for public-private partnership (PPP) 
projects. 
• Establishes a PPP committee, whose functions would include 
providing transaction approvals for proposed PPP projects, 
developing best practice guidelines for PPPs, advising the 
Minister of Finance on matters related to PPP projects, 
overseeing the functioning of the PPP unit and (in consultation 
with the Attorney General) providing clarification on matters of 
interpretation under the Act. 
• Regulates PPP projects through the stages of initiation, 
preparation, procurement, conclusion of the PPP agreement and 
its implementation. 
• This Act applies to the initiation, preparation, procurement, 
management and implementation of public private partnership 
projects. 
 
Public Private Partnership 
Regulations 
• Regulations made in terms of Public Private Partnership Act 4 of 
2017 section 40(1) 
• Came into force on date of publication: 18 December 2018 
 
9 The MoHSS (2013) describes PPP as a government service or private business venture, which is funded and 
operated through a partnership of government and one or more private sector companies. From the health 
sector perspective, PPP is a means to bring together a set of actors for the common goal of improving the health 
care of a population based on the mutually agreed roles and principles 
10 Namibia PPP Act is available at https://laws.parliament.na/cms_documents/public-private-partnership-




Government Notice 353 of 
201811 
• Cover PPP initiation: unsolicited proposals, appointment of 
project officer and appointment of transaction advisor 
• Cover feasibility assessment: Management of contingent 
liabilities and revenue sharing or revenue support mechanisms 
• Provides PPP project procurement and implementation 
mechanisms 
National Development Plan 
5 (NDP5) 
 
• Published shortly before implementation of the Act on 31 May 
2017 
• Serves as Namibia's blueprint for national development between 
2017 and 2022. 
•  
Source: Public Private Partnership Act, No. 4 of 2017, Macdonald (2018). 
The implementation of the Public Private Partnership Act, No. 4 of 2017, coupled with the above 
recent developments (among others), indicate a significant shift in the last few years to achieve some 
of Namibia's infrastructure development goals through a binding set of legislative provisions aimed at 
the government deriving efficiencies (including value for money) from the involvement of the private 
sector (MacDonald, 2018). 
Inkumbi (2019) noted that governance mechanisms for PPPs are evidently thriving in Namibia, 
however there is room to further develop the field of enterprise, particularly with regard to revenue 
streams for projects, which entail more than the initial capital projects. The Namibian government has 
recently received funding from the African Development Bank for the Institutional Strengthening for 
Public-Private Partnerships project to, among other things, provide capacity building, technical 
assistance and advisory services to assist the Namibian Government in operating its PPP framework 
(MacDonald, 2018). A key focus of this project is to fund technical assistance for pilot projects in an 
attempt to address one of the key challenges faced by African governments procuring projects under 
burgeoning PPP laws or frameworks: the limited expertise on the part of contracting authorities and 
limited knowledge regarding best practices (ibid). 
 
However, Inkumbi (2019) argues that one of the core aspects that challenges the concept of PPPs is 
the idea that the state should be the sole provider of services that are traditionally considered to be 
public services. By accepting that certain capital projects and services can be developed and rendered 
by the private sector, public sector resources can be directed elsewhere. Examples of this at work can 
be found in private education, and private medical facilities in Namibia. 
 
As indicated in Table 19 above, the projects identified in the National Development Plan 5 (NDP5) will 
require estimated funding of NA$164 billion which, according to a ministerial statement on the NDP5 
implementation plan, will be funded from several sources, one of which is private-sector funding 
through PPPs (specifically for land servicing and infrastructure construction, such as water, roads, 
sewers and electricity). 
 
Since independence, private finance has been injected into telecoms, power and port expenditure, 
while large investments in mining, smelting and refining infrastructure have mostly been funded by 
multinationals. According the Commonwealth Governance (2019), examples of public–private 
participation are limited, but include energy projects, mining, desalination, mobile 
telecommunications and the Targeted Intervention Programme for Employment and Economic 
 
11 Namibia PPPs Government Regulations available at https://laws.parliament.na/cms_documents/public-





Growth (Tipeeg). The Deutsche Gesellschaft für Internationale Zusammenarbeit (GIZ) has funded 
more than NAD3 million on public–private partnerships in Namibia with three current private partners 
– NamPost Savings Bank, Pupkewitz Megabuild and BFS Nampro Fund Manager. Namibia has little in 
the way of dedicated public–private partnership policy framework, something the Government has 
pledged to address. Development achieved via public–private partnerships is in line with Namibia’s 
Vision 2030 to raise the living standards of the Namibian people to those of the developed world by 
2030.  
 
MacDonald (2018) highlighted that, utilizing the funding procured under the Institutional 
Strengthening for Public-Private Partnerships project, the Ministry of Finance is in the early stages of 
procuring transaction advisory services for a PPP for the redevelopment of an office building for the 
Ministry of Justice. If implemented, this would be the first PPP project to be successfully procured 
under this new legislation. Inkumbi (2019) pointed out that in Namibia public-private partnerships will 
progressively play a vital role in closing the development gaps. The author further argued that when 
managed effectively, PPPs not only provide much needed new sources of capital, but also bring 
significant discipline to project selections, construction, and procedures. Table 20 presents some of 
the PPPs projects in the construction sector prior to the new legislation. 
 






























By 2022, Namibia continue 
to be safe, secure, and 
peaceful and upholding the 




















The objective of this 
project is to construct staff 
accommodations at Dobe 
Border Post, The 
beneficiaries will be 
immigration officials based 
at Dobe Border Post. The 
main components are: 
Construction 16 flats, 2 






















To construct a proper 
Forensic Laboratory with 
essential facilities. The 
beneficiaries are: Police 
members and the public 
while the project 
components include: 
Feasibility study, 
Documentation, design and 




























To build a new primary 
school in order to 
accommodate 800 learners 
from Ehangano. The 
beneficiaries are: learners 
and teachers and the 


























To construct and upgrade 
Primary Health Care Clinics 
nationwide to improve 
service delivery, reduce 
mortality and morbidity 
through the principles of 
primary health care 
services. The components 
are: construction of newly 
approved PHC clinics and 
staff accommodation, 
upgrading of existing PHC 
clinics & staff 




































By 2022, Namibia's Health 
Adjusted Life Expectancy 
(HALE) has improved from 
































General refurbishment of 
the facility, to upgrade the 
general wards (male & 
female) and staff 
accommodation. The 
project will improve access 
to health services for the 
community of Otjiwarongo 
as well as for the general 
population of the 





































By 2022, Namibia has an 
integrated mining industry 
value chain doubling the 
share of valued added 






















Construction of services 
infrastructure (water, 
sewer, electricity and 
roads) in Onayena in order 
to provide households with 
basic services. The Project 
will improve and lead to 
the effective and efficiency 

























To construct services 
infrastructure (sewer, 
electricity, roads and 
water) in Lusese. The main 
components are planning, 
surveying, feasibility 
study, design and 
documentation and 
construction. The 
beneficiaries are the 
residents of Lusese and the 




























The project objective is to 
construct services 
infrastructure (water, 
sewerage, roads and 
electricity) in Opuwo in 
order to connect 
households to municipal 
services to 
have access to basic 
services. The main 
components are: planning, 
surveying design, 
documentation and 
construction. The main 
beneficiaries of the 
projects are residents of 























The Main objective of this 
project is to provide basic 













town. This will highly 
benefit the residents of 
Okahao town, since they 
will have access to 
the services such as clean 
water, proper roads, 
proper sewer and water 
reticulation as well as 
electricity. However, this 
will make it possible for 
NDP5 goals to be 
achieved. The main 
component of this project 










Source: Opawole (2018), Republic of Namibia (2018) 
 
The MoTI (2019) stated that PPP projects such as those listed in Table XX above serve as an engine for 
achieving the social and economic objectives of the Government of Namibia, such as employment 
creation, pro-poor development, inequality reduction, development of Small and Medium Enterprises 
and in particular the Transformation Economic and Social Empowerment Framework (TESEF). The 
execution of the PPPs projects is done by responsible institutions and the success of the 
implementation of the projects is highly dependent on the commitments of the executing institutions. 
To underscore the importance of commitment, the Government of Namibia, has ‘‘called upon all 
partners that are directly and indirectly involved in the implementation of the projects to redouble 
their efforts and ensure that the prioritized programmes and projects are finalized on time to allow 
for other important programmes and projects to be implemented in the years to come’’ (Republic of 
Namibia, 2018). 
 
Health sector landscape and PPPs 
With respect to the health sector, at Independence in 1990, Namibia inherited a fragmented health 
system based on racial segregation. The health systems’ financial, physical and human resources were 
ill-distributed geographically, by level and type of service provision resulting in a concentration of 
infrastructure and services in the urban areas. This created inequalities in the access of health care 
services. These services were more of a curative nature and were managed by the Second Tier 
Authorities that were running parallel programmes. The PPP Act seeks to address some of this 
imbalance. Namibia is situated in South West Africa and is bordered by Angola, Botswana, South 
Africa, Zambia Zimbabwe. Data from 2016 show a population of around 2.5 million people.  According 
to Ministry of Health data in 2018, Namibia had 343 hospitals and clinics, as well as 1,150 smaller 
service points (MoHSS, 2019). Although saddled with one of the highest burdens of HIV/AIDS, over 
the last 15 years significant strides have been made in the fight against the pandemic through 
government-led programmes supported by international partners, multilateral support from the 
Global Fund for HIV, WHO and bilateral funding from the United States (USAID) and the United 
Kingdom’s Department for International Development (DFID), amongst others. Data from 2016, show 
that Namibia is well on track to reaching the UNAIDS 90-90-90 goal by 2020.  70 percent of the 
population had been tested for HIV of the HIV positive, 67 percent of adults and 90 percent of children 
are receiving antiretroviral (ARV) treatment (references). It must be acknowledged that in 2003, 
Namibia had one of the highest global incidences of HIV, and current statistics bear testament to the 




challenges, including drugs access, circumventing market deficiencies, bypassing health system bottle-
necks and improving treatment access and cost-efficiency.   
Box 2: Summary - key socio-economic and health system indicators 
Source: CIA World Factbook (2019): https://www.cia.gov/library/publications/the-world-
factbook/geos/wa.html 
 
Despite having one of the highest burdens of HIV globally, and a high prevalence of HIV associated 
opportunistic diseases, notably tuberculosis, Namibia has made significant advancements in 
implementing policies that directly address these challenges through enabling health service provision 
across the continuum of care; in prevention, testing, treatment and monitoring.  A key feature of 
Namibia’s efforts in the global fight against HIV is that the government has contributed up to 65 % of 
the requirements for these multiple programmes, in a classic example of state-led health 
development, unique only to a few African countries (African Health Observatory, 2019). This 
approach appears to be particularly effective in setting the tone for the establishment of health-
orientated PPPs through structural cooperation strategies involving key partners such as PEPFAR, 
USAID and the Global Fund for HIV/AIDS (MoHSS, 2019).  
 
Namibia’s healthcare provision is based on a four-tier system comprising of healthcare posts/outreach 
points, clinics and health centres, district hospitals and referral hospitals complemented by a sizable 
private sector and faith-based/mission hospitals (see table XX).  Noteworthily, whilst Namibia has a 
well-developed private health care provision in the urban regions of Oshana, Kavango, Erongo and 
Khoma, it is however not fully deployed to improve access of services to the mainly rural population, 
which is sparsely distributed across the country’s vast land area of 823, 290 square metres (Pareko et 
al., 2018).  In this background, the key priorities identified for improvement by the government 
include: 
• Service delivery redesign – primary health care provision 
• Service coverage and reach (particularly for maternal and child health), ambulance, dental, 
and laboratory services, technical and clinical capacity 
• Addressing infrastructural constraints, information technology, supply chain design and 
management 
• Technology sustainability and future-proofing 
• Organisation and coordination of health service providers 
• Incentivising innovation – innovative health financing 
• Integration of services across disease areas 
Some of these priorities inform the structuring and delivery of PPPs in other sectors of the economy 
as presented in Table 20, and those in the health sector, shown in Table 21 below: 
Total population (2018) 2,533,224 
Gross Domestic Product (GDP) US $ billions (2017) 13.24  
GDP per capita purchasing power parity US$ (2017) 11,200 
Life expectancy at birth male/female (years, 2018) 62.7/66.2 
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Informed by international health objectives, a defining feature of these embryonic partnerships is that 
though driven by foreign policy goals and developmental cooperation, they take into consideration 
NPPP Policy provisions, emphasising equality between partners.  In these efforts, the focus has been 
on maximising human resources and skills, meeting health and developmental needs, improving local 
capacity and reducing dependency by promoting Namibia’s advancement of its own developmental 
agenda. There however, was some inertia in take-off, as exemplified by the sluggish enactment of the 
PPP act, discussed earlier. Meanwhile, below, we give further details on some of the PPPs presented 
in Table 21 above.  
 
Access to Finance: PharmAccess Foundation Namibia (PAFN) 
Areas Covered by Partnership Partners Involved Primary Purpose of 
Partnership 





Profit Org (PAFN) & Academia 
(NUST) Government of 
Namibia 
Improving access to basic 
health care services through 
more effective and inclusive 
healthcare finance 
Developed by authors with data from interviews and MoHSS (2019): 
In 2010, PAFN launched the Mister Sister Mobile Health Service, a unique PPP arrangement that 
leverages both governmental and private sector resources to cover the cost of service delivery and 
has played a vital role in upgrading health infrastructure and the quality of services delivered to rural 
populations in Namibia. 
Access to services:  Namdeb hospital in Oranjemund and Rosh Pinah 
Areas Covered by Partnership Partners Involved Primary Purpose of 
Partnership 




   Private and Mission 
hospitals  
   Specific 
programmes: 
Demand creation 













Service delivery, quality 
improvement, infrastructure 
upgrade  
Private Mining Companies 
(Orangemud and Rosh Pinah) 
and Government of Namibia 
through Ministry of Health and 
Social Services 
Health service for company 
workers and community 
members 
Developed by authors with data from interviews, SHOPS (2012) and MoHSS (2019): 
Oranjemund is a “company town” located in the restricted diamond area, which is off limits to those 
without the proper permit. To serve its workers in this isolated location, Namdeb operates its own 
hospital and clinic. MoHSS runs a primary care clinic in the town for those not employed or insured by 
Namdeb. When patients cannot be treated by the nurses at the public clinic, they are referred to the 
Namdeb hospital, and MoHSS pays for their care under a negotiated agreement (SHOPS, 2012)12.  
The partnership at Rosh Pinah is an attempt to give public patients access to mine-operated medical 
facilities. The fully equipped outpatient clinic founded by the two mines at Rosh Pinah has two 
physicians and a full range of support personnel. It also has basic diagnostic equipment (X-ray, 
ultrasound) that is not available at the nurse-staffed public clinic. An agreement between the regional 
MoHSS and the private clinic was facilitated by PharmAccess Foundation and Boston University. The 
rapidly expanding uranium mine at Rosh Pinah offers a similar opportunity for partnership.  
From the data on PPPs for health in Namibia that this study managed to consolidate, a number of 
observations stand out. Firstly, as the governance terrain takes shape, questions still remain 
concerning co-location arrangements and the most feasible mechanism for private sector 
engagement in Namibia. Relatedly, there is symmetric division of power in projects relying on external 
donors mainly (PEPFAR funded HIV programmes), which is part of a broader narrative on the 
patchiness of information regarding the contractual mechanisms underpinning PPP relationships and 
lack of clarity of the precise structure for engagement between the government and international 
donors. Further, while opportunities for innovative private sector finance in the design, building, and 
financing of large infrastructural projects are highlighted as a key driver for PPPs, they are as yet not 
clearly articulated or visible. Development and implementation of partnerships need competencies 
and dedicated resources. Meanwhile, the government is taking a leading role in leveraging the 
catalytic role of PPPs, through for example, leading infrastructural projects and seeking to repurpose 
(integrate) vertical driven programmes in the long-term (MoHSS, 2014). In addition, despite a small 
domestic market and capabilities for local pharmaceutical production, government policy has created 
preferential market access for local producers such as Fabupharm (producers of creams, ointments 
and syrups) and Comex, condom producers for the local and sub-regional market (MoHSS, 2019).  
  
 
12 SHOPS Project. 2012. Namibia Private Health Sector Assessment. Brief. Bethesda, MD: 





5.5 Zambia.  
Zambia is a lower-middle income country, with a population of nearly 18 million in 2019, having gained 
its independence from Britain in 1964. Although Zambia has grown in economic status since gaining 
its independence in 1964, and currently boasts a GDP of USD 27.0 Billion with a 6.0% annual growth 
due to an increase in mining and industrial activities, disproportionate income levels are observable 
between the rural and urban population with poverty levels in rural areas at 70% compared with 
between 20 and 30 percent in urban areas which include Lusaka the capital city, Kitwe, Ndola and 
Livingstone (World Bank, 2019).  
 
Given the changing economic, social and political environment, coupled with globalisation and budget 
constraints, public-private partnerships (PPPs) have become unavoidable and indeed desirable in 
many countries worldwide (School of Built & Natural Environment, 2011). PPPs are now commonly 
used to accelerate economic growth, development and infrastructure delivery and to achieve quality 
service delivery and good governance (ibid). Zambia, like many other developing countries whose 
Gross Domestic Product (GDP) and Per Capital Income (PCI) cannot sufficiently support the required 
social and economic development is not an exception. Zambia has embraced PPPs as a project delivery 
method (Ngoma et al., 2014) and has engaged in different forms of PPPs in the transport, construction, 
health and energy sectors among others (ZDA, 2014).  
 
Mukela (2010) stated that in 2004, the government of Zambia recognised the need to provide 
infrastructure and other public services through PPPs. Although various forms of PPPs had been 
implemented previously, there was no structured legal policy framework at the national level. 
According to the Zambia Development Agency (2014), the Zambian Government acknowledged that 
the use of PPP13 tools and techniques to finance infrastructure development could enhance public 
service delivery. As such, in December 2008 the Government approved a Policy Framework for the 
implementation of PPPs in Zambia. Following the Policy pronouncement by Government, Parliament 
in August 2009, passed the PPP Act No. 14 of 2009, which aims to promote and facilitate the 
implementation of privately financed public infrastructure projects in Zambia. The PPP Act, therefore, 
provided for the establishment of the PPP Unit as a directorate under the Ministry of Finance and 
National Planning (MOFNP). All PPPs henceforth are initiated and implemented under the PPP Policy 
and Act of 2009. The Act was developed and enacted into law in order to put into effect the need to 
use PPPs as strategic tools and means of complimenting Government efforts to mitigate the limited 
resources towards economic programmes (Government of the Republic of Zambia, 2009). Thus, the 
Government’s vision on PPPs is:  
 
“To have well developed and maintained quality socio-economic infrastructure and related services 
that enhance the Zambian people’s livelihood and effectively contribute to national development 






13 From the Zambian perspective, a PPP is defined as an arrangement between public and private sectors with 
clear agreement on shared objectives for the delivery of public infrastructure and/or public service by private 
sector that otherwise would have been provided through traditional public sector procurement (PPP Policy and 
the Act of 2009). 
14 https://ppp.worldbank.org/public-private-






Implementation challenges for PPPs in Zambia 
 
Zambia has been facing serious funding constraints in implementing projects backed by public 
finances (Muleya and Zulu, 2009). ZDA (2014) argue that the major constraints being faced in the 
implementation of PPPs in Zambia are mainly related to factors affecting the supply side of PPP 
projects, resulting in obstacles to mobilize private sector resources. These constrains include the 
following: 
 
• Political Champions required in driving the PPPs agenda. ZDA (2014) highlighted that Political 
Champions are necessary to marshal the support of stakeholders in the implementation of the 
PPP projects. In Zambia, key ministries that would be in a better position to play the Political 
Champion’s role include the Ministry of Finance, Ministry of Commerce, Trade and Industry, and 
the Ministry of Transport, Works, Supply and Communications. ZDA argue further that unless the 
requirement of these Political Champions is recognised and addressed, even the technical staff in 
ministries, departments, agencies, and local government will not move at a speed adequate 
enough to implement the PPPs in Zambia. 
 
• Lack of capacity in Government to undertake PPP projects. ZDA (2014) reviewed the PPP 
implementation process in Zambia and argued that there is limited capacity in Government to 
implement PPP projects. The complex and long-term nature of most PPP projects demand skills 
and understanding beyond that of traditional contract management or administration. However, 
the Cabinet’s approval to subsume and institutionalize the PPP Unit functions into the Zambia 
Development Agency in November 2013, addressed this challenge to a greater extent and the ZDA 
now play a critical role in coordinating PPP projects between various key players and Contracting 
Authorities in Zambia.  
 
• Political-bureaucratic constraints and risks. Ngoma et al. (2014) argue that in the Zambian PPP 
Act, political risks, such as the discontinuation of concessions, tax increases, inappropriate tariff 
implementation and increases, and enforcement of new government policies do not appear to 
have been addressed. While the Act stipulates the administrative procurement procedure, it does 
not provide specific project strategies and expected results from the PPP process. 
 
• Financial constraints. Muleya and Zulu (2009)’s study on delivering infrastructure development 
using PPPs in Zambia argue that the Zambian PPP Act of 2009 does not provide any financial 
measures to address such constraints and risks. Although the act provides clauses prescribing the 
criteria for evaluating financial and commercial proposals, it lacks direction on appropriate PPP 
finance structures to ensure revenue risk reduction and user affordability of possible charges. 
 
• ZDA (2014) highlighted that lack of clear guidelines and regulations to guide contracting 
authorities and the private sector in the implementation of PPPs as one of the major constraints. 
ZDA’s argument was based on the fact that since the enactment of the PPP Act of 2009, no 
regulations have been produced to clarify and guide the public and private parties in respect of 
those provisions that require regulations.  
 
While literature has shown some major challenges faced in the implementation of PPPs in Zambia, it 
is worth noting that PPPs provide innovative ways of improving the delivery of socio-economic 
services to the citizenry (ZDA, 2014). A study by Nshimbi and Vinya (2014) on impacts of public-private 
partnership on local livelihoods and natural resource dynamics: perceptions from Eastern Zambia 
suggest that PPPs, if well-structured, have the potential to address both livelihoods and enterprise 




management in tropical Africa. Table 22 presents key legislation and policies supporting PPPs in 
Zambia. 
 
Table 22: Key legislation and policies supporting PPPs in Zambia 
Legislation or Policy Mechanism 
The ZDA ACT No. 11 of 
2006 
 
• Established the Zambia Development Agency whose mandate is 
to facilitate investment by providing effective and 
comprehensive business services facilitation, micro, small and 
medium enterprise development, business development and 
aftercare services as well as market information in order to 
promote Zambian exports. The Act is currently undergoing 
revision to align it with the current trends in investment 
promotion. 
The PPP policy of 2008 
 
• A strategic document that clearly outlines the country’s strategic 
objectives in terms of PPPs and includes, among others, the 
implementation framework 
PPP Act of 2009 
 
• Provides for the participation of the private sector in the 
provision of social sector services and the development and 
operations of public infrastructure; 
• An Act to promote and facilitate the implementation of privately 
financed infrastructure projects and effective delivery of social 
services by enhancing transparency, fairness and long-term 
sustainability and removing undesirable restrictions on private 
sector participation in the provision of social sector services and 
the development and operation of public infrastructure; 
• Establishes a Public-Private Partnership Unit and provides for its 
functions; establish the public-private partnership Council and 
provide for its function; 
• Provides for public-private partnership for the construction and 
operation of new infrastructure facilities and systems and the 
maintenance, rehabilitation, modernisation, expansion and 
operations of existing infrastructure facilities and systems and 
the provision of social sector services; 
• Develops general principles of transparency and fairness in the 
award of contracts by public authorities through the 
establishment of specific procedures for the award of 
infrastructure projects and facilities and provision of social 
sector services and rules governing public-private inception, 
procurement, contracting and management of public-private 
partnerships; 
• Provides for the implementation of public-private partnership 
agreements between contracting authorities and 
concessionaires; and provides for matters connected with, or 
incidental to, the forgoing 
Source: (Government of the Republic of Zambia, 2009; PPP Policy and Act of 2009, p. 79) 
 
As shown in Table 22, the PPP policy of 2008 is backed by the PPP Act No. 14 of 2009 and both the 
PPP Policy and Act provide an enabling environment for various PPPs to be initiated, developed and 
implemented using a number of variants such as Concessions, Lease, Management, Service contracts 





Priority Areas in PPP Infrastructure Investment in Zambia 
 
Table 23 identifies priority areas for infrastructure investment in Zambia. The government has been 
looking at private partners to fund the identified projects (ZDA, 2014). The Government retains a 
significant role in the partnerships as the main purchaser of services or the main enabler of the 
projects. 
 
Table 23:  PPP projects completed or on-going in Zambia in the transport, agriculture, energy and 
health sectors. 
Sector and type of 
PPP 
Facility/Project summary 
Transport – rail 
 
Chingola-Solwezi-Lumwana-Jimbe railway line: Expansion of the existing 
604km railway line to link with Chingola through Solwezi to the border 
town of Jimbe to enhance the transportation of freight and passenger 
traffic and other products using Lobito Bay port in Angola 
Transport – rail 
 
Kazungula-Livingstone railway spur: The development of approximately 
193 kilometre stretch of railway line from Livingstone District, Southern 
Province, (which will run parallel to the border with Zimbabwe, 
Botswana and Namibia) to Sesheke District, Western Province, and will 
connect to the existing Zambia Railways Limited Railway line in 
Livingstone which in turn connects to TAZARA in Kapiri Mposhi, Central 
Province. 
Transport – rail Kafue Lions den: Linking the Zambia Railway line from Kafue (Zambia) to 
Ziwa (Zimbabwe) (341km) the way to the Beira Port as the shortest route 
to the port of Baira in Mozambique. 
Transport  Njanji commuter 
Transport – rail 
 
Nseluka-Mpulungu railway spur: The development of approximately 190 
kilometre stretch of railway line from Mpulungu to Nseluka (within the 
Northern Province of Zambia) connecting to the TAZARA. This will 
provided easy transport to three Districts of the ten in Northern Province 
i.e. Mungwi, Mbala and Mpulungu Districts 
Transport Solwezi via Kasempa-Kaoma-Mongu to Katima Mulilo 
Transport – rail TAZARA Nseluka – Mpulungu port: The railway lines involves linking 
Mpulungu Port to TAZARA line at Nseluka (170km) to facilitate the 
imports and exports from the Great Lakes region to the sea ports on the 
Indian Ocean 
Transport – rail Mchinji/Chipata railway: Extension of the existing railway line to TAZARA 
by 406km- The railway line involves linking the Chipata–Mchinji line 
through Petauke District to the port of Nacala in Mozambique. 
Agriculture Development of Kalumwanga Farming block 
Agriculture Development of Luena Farming blocks 
Energy  Development of Kabompo mini-hydro 
Energy Development of Kalungwishi mini-hydro 




Health  An Ultra-modern Center of Excellence Hospital in Lusaka 
Health  Three diagnostic health facilities in Lusaka, Livingstone and on the 
Copperbelt 
 Source: ZDA, (2014) 
Health System Overview  
 
Healthcare service delivery in Zambia is centred on state and non-state actors, which encompass non-
governmental organisations (NGOs) such as Medicines San Frontieres and the Clinton Health Access 
Initiative (CHAI) amongst others complementing faith-based organisations which mainly run what 
have often been termed ‘mission’ health facilities (Caines and Lush, 2004). Health service provision is 
based on a decentralised health delivery model that is government-led as shown in table 24 (ministry 
of health contributes to 81 percent) of health facilities and 19 percent of the health facilities are 
private (of which six percent are mission type). Public health sector provision is categorised at three 
main levels: tertiary or specialist hospitals (level 3), provincial care (level 2) and district level care in 
(level 1 hospitals).  
 
Box 3: Summary – socio-economic and health system indicators  
Sources: CIA World Fact Book (2019) https://www.cia.gov/library/publications/the-world-
factbook/geos/za.html and WHO 2019 https://www.who.int/countries/zmb/en/ 
 
Since 2000, the Zambian government has spear-headed pro-poor policies and initiatives to address 
central systemic issues such as inequity, lack of access to basic health care, and a high infectious 
disease burden particularly that of HIV, tuberculosis and malaria whist assuring protection against 
financial risk (Phiri and Ataguba, 2014). Notably, government has indicated plans to implement the 
National Insurance Act of 2018 in 2019 (Zambia Budget Report, 2019).  These efforts at driving health 
inclusion have however been hamstrung in the past by a range of challenges including contraction in 
health-sector funding, an increasing poverty gap, inequality, and poor distribution of resources in rural 
areas (Hellowell, 2013; Aantjes et al., 2014). Cumulatively these factors not only adversely impact the 
healthcare system but also reflect the extent to which they are in the first instance intrinsically 
attached to broader economic, social security and health policies (Fleischman and Peck, 2016). Yet 
despite significant improvements government funding has not reached the target threshold for health 
funding (fifteen percent) specified in the Abuja declaration15. Ministry of health figures show that in 
2015, health spending constituted only around five percent of the total health budget. A recent study 
 
15 Head of States from the African Union met in 2001 and pledged to allocate at least 15% of 
their annual budget to drive health sector service delivery and improvement (WHO, 2010). 
Total population (2019) 18, 012, 770 
Gross Domestic Product (GDP) US$ billions (2017) 25, 71 
GDP per capita purchasing power parity US$ (2017)                                                                                                                                          4,000
Life expectancy at birth male/female (years, 2018) 51.4/54.7 





by Chitah et al., (2018) offers vital insights into the range and scale of current and emerging systemic 
issues faced by the health sector.  
 
These authors show that despite years of sustained health reform efforts, the government’s vision of 
‘equity of access to quality health services’ has not been realised, and worse still, this is unlikely to be 
achieved soon. These researchers conclude by advocating for ‘minimal risk protection’ through the 
adjustment of ‘supply and demand’ as an avenue of enhancing both equity and health care access. 
Such perspectives create a distinct impression that highlights ‘equity of access’ as the ‘Achilles heel’ 
against efforts to attain hard targets such as the health-related sustainable development goal (SDG) 3 
which aims at reducing infectious diseases and non-communicable diseases by 2030.  
 
Zambia’s large geographical area must be recognised as the first impediment against equitable access 
to health services. The varied terrain and the relatively sparsely distributed population mean that the 
subsequent organisation of settlements poses significant logistical challenges from the perspectives 
of transportation and the referral networks linking the various healthcare centres. This means that 
basic health facilities may not necessarily be within easy reach for the population, particularly for rural 
dwellers of whom only 46 percent live within five kilometres of a health facility (Zambia Statistical 
Office, 2011).  These access-related issues are exacerbated by the underlying issue of a fragmented 
health system, in which human resources skills are in short supply, funding is chronically inadequate, 
and infrastructure is relatively weak, factors which cumulatively generate contexts of risk and 
uncertainty for citizens (WHO Cooperation Strategy: Zambia, 2013).  
 
Table 24: Types and providers of health facilities in Zambia (2015). 
 
Health Facilities (Provider) Total Percentages (%) of 
Health Facilities 
Ministry of Health (MoH) 1 590 81 
Mission 116 6 
Private 250 13 
Grand Total 1956 100 % 
Health Facilities (Type)   
Level 3 Hospitals (Tertiary/Specialist) 6 <1 
Level 2 Hospitals (Provincial) 19 <1 
Level 1 Hospitals (District) 84 4 
Rural Health Centres 1131 58 
Urban Health Centres 409 21 
Health Posts 307 16 
Grand Total 1956 100 % 
Source: Ministry of Health Zambia (2015) 
 
The need for PPPs in Health 
As highlighted in the previous section, the public health system of Zambia, faces significant capacity 
and resource limitations to address health service related challenges on its own. Zambia has embraced 
partnerships since independence in 1964 through which private health care providers identify 
profitable undertakings and government provides regulation to guide their operations in the interest 
of the Zambian people. Through partnerships, private companies donate resources as part of their 
Corporate Social Responsibility. The Church in Zambia (Catholic and Protestant) provides health 
services on behalf of the Zambian government. In return, the government offers support to Church 




Frequency, distribution and contextual realities of health PPPs in Zambia 
 
Table 25 presents the examples of the PPP initiatives identified through interviews and a review of 
the available literature across the dimensions of; research and innovation generation, innovation and 
technology development, translation and commercialisation, infrastructure design and development, 
and health care service delivery. The PPP mode most visible and extensively reported in the literature 
on health systems, is on healthcare service delivery, particularly across the different components of 
the healthcare continuum including drug access, diagnostic access, and transportation.  
 
Table 25: Examples of health system PPP initiatives in Zambia  
 
Source: authors from interviews and MoH, 2019 
 
Details on selected Examples of Zambian Health PPPs 
Broadly, health PPPs in Zambia have been initiated for a number of reasons, including, 
complementarity - filling critical but commercially viable gaps (e.g. Medical Diagnostic Laboratories 














Ministry of Health 
(Zambia has accessed 
GAVI funding to drive 
the roll out of the 
pneumococcal vaccine 
Zambia is 10 th country 
to introduce measles 
second dose vaccine 
Through innovative 
finance mechanisms 
access to affordable 
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(IDRC), fully fledged 
NGO in 2012.  
Construction of 
Supply chain and 
distribution 
regional hubs in 
Chipata, Mpika, 
Mansa, and 
Choma.  Medical 
Stores Limited 
(supported by 
Global Fund, USAID 
and European 
Union). 





Malaria (2001 -2011) 
WHO/Novartis public 
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HIV drugs, malaria 
and tuberculosis 
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(CHAI) 
Health system  
   Mission Hospitals 
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care); Supporting health services (E.g. commercial banks and others); or Expanding or building 
facilities e.g. Multi-nationals- eg such as Copper Mines companies.  
Training and health delivery: Churches Health Association of Zambia (CHAZ) 
Areas Covered by Partnership Partners Involved Primary Purpose of 
Partnership 
Training, diagnostics, 
preventative, curative and 
palliative services  
Private-Non-Profit 
Organisation (CHAZ) and 
Government of Zambia 
Providing access to health 
services in the rural and hard to 
reach area for the people of 
Zambia 
Source: Interviews and MoH (Zambia), 2019 
The Church is the second largest provider of health services in Zambia with an estimated coverage of 
over 50% in rural areas and about 30% nationally. The CHAZ was formed in 1970 and is currently an 
interdenominational umbrella organisation of more than 150 churches from all the 10 Provinces of 
Zambia. It runs 36 Hospitals, including 9 Nurse Training Schools, more than 80 rural health centres and 
more than 30 Community Based Programmes on Health Services Coverage. Registered members of 
CHAZ operate on a Not-for-Profit basis and within the national health policy framework. CHAZ has 
held Principal Recipient (PR) Status for more than 15 years for the Global Fund Mechanism in Zambia 
for all the 3 disease components: HIV/AIDS (including ART), Malaria & TB, managing multi-million 
dollar grants in the process and complementing government’s efforts in health service delivery.  
Training and R&D - Zambart 
Areas Covered by Partnership Partners Involved Primary Purpose of 
Partnership 
Training, research and 
development, diagnostics, 
preventative, curative and 
palliative services  
Private-Non-Profit 
Organisations (Funders, WHO 
and CBOs), Academia - local 
and international (LSHTM and 
UNZA) and Government of 
Zambia 
Healthcare research, 
managerial, scientific and 
technical capacity building to 
reduce the public health 
burden of HIV/AIDS and TB 
Source: Interviews and Zambart.Org (2019) 
Zambart is a Zambian research organisation established in 2004 from a research collaboration 
between the School of Medicine University of Zambia and the London School of Hygiene and Tropical 
Medicine (LSHTM) that spans over 20 years. From the initial studies of the impact of HIV on the clinical 
presentation and outcome of Tuberculosis, the scope and partnership of the research have expanded 
widely. Zambart actively partners with the Zambian government through direct collaboration in 
healthcare research, and works closely with other research organizations and academic institutions 
within Africa, and worldwide to help innovatively reduce the public-health burden caused by the dual 
epidemics in resource-limited communities in Zambia and beyond. 
The prevailing view in global health frames Zambia as a preferred site for PPPs is based on its 
perception as a relatively stable environment for health and development efforts, despite sustained 
pressures from such factors as inequality, widening gap between the rural and urban population and 
broader national economy issues such as inconsistent exports (Fleischman and Peck (2016). The 




various components of health delivery, including prevention, diagnosis and treatment programmes, 
with successful partnerships established with international partners which include pharmaceutical 
giants such as Merck, organisations such as the Clinton Health Access Initiative (CHAI), and faith based 
organisations which have an established footprint of delivering health through hospitals and clinics 
over the last century.   
 
However, the health policies and initiatives have mainly targeted high profile and diseases such as 
HIV/AIDS, tuberculosis and malaria on account of their high prevalence, and in alignment with donor 
preferences. Even then, there have also been concerted efforts at integration and harmonisation of 
initiatives, programmes, even though this has not been reflected in the financing practices and 
mechanisms. Thus, the evidence and experience of the PPP model in Zambia paints a conflicting 
picture that reflects some of the predominant practical challenges faced by the Zambian government 
in re-orienting health policies, structures and service provision towards a system that can 
simultaneously address infectious and non-communicable diseases (Aantjes, 2014).  
 
PPP initiatives in Zambia over the last fifteen years have been dominated by overt government efforts 
to engage the private sector in addressing research and development, pharmaceuticals manufacture, 
procurement, distributing of medical products and health service delivery amongst other avenues of 
health systems strengthening.  Despite the significant advances achieved in establishing partnerships 
with the non-profit sector, it is easily observable that such success in engagement efforts were not 
replicated in the private sector (Caines and Lush, 2004). Several explanations have been proffered to 
explain the mixed outcomes of success counterbalanced by lacklustre health system impacts 
attributable to PPPs. Our findings, corroborated by other researchers, identifies that regarding the 
impact of PPPs, the underdeveloped state of Zambia’s private sector explains, at least in part, the lack 
of engagement by local investors, and why, furthermore initiatives rarely extend or commit beyond 
massively dampened versions of corporate responsibility (Fleischman and Peck, 2016).  
 
The short-term orientation of PPPs has been criticised widely. Partnerships need long-term 
commitment, eg the successful cases at UNZA or NISIR. The central criticism for short-term 
partnerships is identified as the inadvertent weakening of institutional and local capacity, on 
completion of donor missions. Concerns have also been raised regarding the heavy reliance on 
external donors, whose motivations for participation in health initiatives do not necessarily mirror the 
long-term sustainability and scalability goals advanced by government (Clinton and Sridhar, 2017). A 
clear example of such mismatches in policy and strategies, is the preference by external organisations 
to focus on vertical or issue-focused approaches rather than the more holistic (system-wide) 
programming. Whilst the rationale underpinning these preferred approaches is understandable (i.e. 
vertical approaches can cut across the inertia associated with horizontal/ holistic programmes) one 
unintended consequence of the engagement between the public sector and its international 
benefactors is the ‘undercurrent tensions’ often ignored on account of the perceived benefits to 
health service delivery. For example, through vertical programmes anti-retroviral drugs for HIV have 
been available in Zambia since the early 2000s. Through such arrangements and due to transaction 
and opportunity costs, verticalised procurement and distribution systems were developed for ARV 
drugs such as Viramune® (designed to stem the vertical transmission of HIV). Likewise, access to 
Fluconazole (Diflcucan ®) for oesophageal candidiasis was developed under similar discount 
arrangements, a national programme outside of the conventional procurement and distribution 
system. Establishment of such mechanisms, whilst clearly beneficial in greatly enhancing access to 
medicines, also introduced skewed market dynamics with the potential to cause system leakages 
(Aantjes et al, 2014). The differential pricing between donor-procured and private sector sourced 
medical products creates a risk of pilferage from the PPPs. In other words, this creates and sustains 
two different markets, and tensions between the provision of drugs, and services with separate pricing 




confirms that while management of the PPPs remains a challenge, rapid technological and market 
developments are reconfiguring user needs and demands in ways that make it increasingly impossible 
for single partners to keep up, e.g. the types of service delivery facilities that new populations of 
patients are willing to pay for are driving actors in the health sector to privatise and modernise their 
facilities. There is a lot of learning from the South African health system in this regard.  
 
5.6 Overarching narratives on relevance and salience of PPPs for health in southern Africa 
As we draw towards some conclusions and recommendations from this study, we take a moment to 
reflect on some of the broader narratives shared by respondents which encapsulate how, as Gideon 
and Unterhalter (2017) argued ‘PPPs will be a feature of the policy landscape around development 
assistance for the next 15 years’. 
‘Partnerships are not much of a choice in most cases because no single actor would have the 
capacity or reach to cover all the areas that you mentioned … from making products to making 
them available to patients with different levels of treatment needs. Partnerships are a 
necessity; the biggest challenge though is that often there isn’t sufficient time devoted to 
creating and deploying the best form of partnership for a given scenario. We tend to rely on 
generic approaches to and models of partnership which often to not take into serious 
consideration the realities surrounding particular health sector challenges in our countries’ 
(Pharmaceutical Manufacturers’ representative, Aug 2019) 
‘We are a partnership, and our mandate includes encouraging countries to enter into 
partnerships that are beneficial for the health sector. The starting point should not be the 
partnership, but the challenge that the partnership intends to solve. There must be a 
compelling case that without the partnership, outcomes for the partners and those they 
intend to serve, would be poorer’ (Regional Economic Community official, Aug, 2019) 
‘We intend, through partnerships, to close gaps in capacity so that we can produce sufficient 
and appropriate quantities of medicines in good time. It is true that sometimes we do not 
structure the partnerships correctly, putting too much emphasis on certain parts of the value 
chain, and not the rest of the value chain, which may then result in bottlenecks elsewhere. 
Ideal partnerships should be catalytic, i.e. leading to formation of appropriate partnerships 
elsewhere where needed, that way ensuring that the whole complex functions well. Policy 
plays a crucial role in the creation of such partnerships, as well as the collective will of actors 
in the sector’ (Pharmaceutical company representative, July 2019) 
‘We are there to facilitate, and yes, as much as policy does need to be instrumental in 
facilitating the emergence and operations of partners, as policy makers we rely to a great 
extent on the good will of actors in their quest for policy-led models of operation, or for the 
way in which policy shapes the business environment. It is not possible to be prescriptive 
because at the end of the day actors, especially external actors or private actors, tend to drift 
towards environments where they can maximise returns on their investment. This may not 
always be in line with our broader socio-economic development goals, but in some cases 
government has to be in or approve certain partnerships with the hope of more inclusive 
intensions as time goes on’ (Government official, Namibia, Sept, 2019) 
‘It is good to realise and accept that partnerships do not always work, that they fail even after 
starting off well, and also that their purpose will come to an end. Most of our policies seem 
to assume that partnerships are perpetual or that they should be forced to continue to exist, 




imperative to continue to exist. We need to have the boldness to discontinue certain 
partnerships, across all levels from the global to the local’ (Government official, Zambia, July, 
2019). 
‘How do we make existing partnerships adaptable? We cannot be forming new partnerships 
for every new challenge. On the other hand, existing partnerships often accumulate a lot of 
baggage as they carry on, so it’s about getting a good balance between adjusting the old or 
creating a new arrangement’ (Pharma wholesaler, Botswana, July, 2019) 
‘Among the biggest and on-going challenges that we face is the fact that we have a wide 
diversity of activities that define the work we do, all broadly fitting into clinical and non-clinical 
work. The kinds of partnership that would work in such areas are therefore different, and even 
for non-clinical work, our requirements as a stakeholder are different from what other 
stakeholders would require. For example, when it comes to construction, renovations and the 
like, we would need some kind of transient partnerships because of the specialisations that 
our final construction products require’ (Health facility respondent, Zimbabwe, Aug 2019) 
‘The future challenge is to remain attractive as clinical research partners to private industry 
and to maintain a consistent level of research quality across sites so that knowhow is both 
transferable, shared and sustained.  In addition, new technologies are entering clinical 
research increasingly over the next 5-10 years so it will be important that the partnerships get 
involved so as not to become outdated. Examples are Big Data mining efforts that could be 
done by pooling study information (Clinical Trials researcher, South Africa, July, 2019.  
These views lay bare the conundrum that faces the role of PPPs in serving as investment vehicles and 
financing mechanisms for building a competitive African health sector that is interlinked with a viable 
pharmaceutical industry complex. Drawing from the 6-month study which sought and analysed 
primary and secondary evidence from five southern African countries, this paper has closed an 
empirical gap on health PPPs by shedding some light on the issues above and related others. The next 
session presents the paper’s main conclusions and recommendations.  
 
6.0 Conclusions and Recommendations 
The paper has been set in the context of post-2000 period which has signified an important shift in 
the normative dimension of what constitutes basic health in low-and-middle-income countries, from 
the previous reliance on the syndromic management of disease to the current use of diagnostic and 
other evidence-based treatments central to the delivery of public health.  In that light has emerged a 
greater need to understand the contextual factors vital to achieving and sustaining the delicate 
balance between increasing value for money and advancing public health goals in the face of an 
intractable set of current and emerging health system challenges (poor funding, fragmented and weak 
infrastructure, skills shortages), and a high burden of diseases such as HIV/AIDS, malaria, tuberculosis 
(TB), neglected tropical diseases (NTDs) such as trypanosomiasis and bilharzia added to which there is 
a growing incidence in non-communicable diseases (NCDs) such as diabetes, cardiovascular issues and 
cancers.  Consequently, one of the most distinctive changes in the global health landscape has been 
the increase in the number of special organisational structures called public-private partnerships 
(PPPs) involving international organisations and private sector partners linked in some way with 
service provision, across the different components of health care; pharmaceutical production, 
procurement and delivery, community health, infrastructure, information technology and human 





Despite an increase in research investigating the roles of PPPs globally and elsewhere in Africa, there 
is limited understanding on the distribution and make up of PPPs in Southern African countries. This 
paper sought empirical evidence from five countries in this region namely Botswana, Namibia, South 
Africa, Zambia and Zimbabwe to explore potential avenues on how health PPPs can be more broadly 
deployed to leverage private sector resources and expertise to drive government goals of optimising 
the efficiency and cost-effectiveness of the PPP model in health service delivery. Southern African 
countries, previously viewed as the epicentre of HIV/AIDS were viewed as an important source of 
insights, experiences and lessons for global health researchers and policymakers on the role of PPPs 
in building competitive health-industry complexes in the study countries and other LMICs.   
 
This paper has established that while the core provision of healthcare services is primarily viewed as 
the responsibility of governments, policymakers increasingly recognise that in these evolving health 
contexts, private actors’ capital and expertise are a central driver for improving both cost-efficiency 
and overall health system effectiveness, through enhanced access to services and the introduction of 
innovative technologies and service delivery modes.  In the last two decades, for example, in all the 
study countries, the view that governments have a role in attaining and sustaining the appropriate 
balance between public and private sector resources both for financing and managing health services 
has taken centre-stage as a viable avenue for ensuring the optimal deployment of resources to 
advance public health goals, across the dimensions of equity, access, cost-effectiveness and quality of 
healthcare provision. Public private partnerships in health have thus been proffered as vital 
mechanisms through which governments can deploy and leverage private sector resources and 
expertise not only to deliver public health objectives in broad terms but to judiciously balance and 
maximise public and private sector strength such as accelerated decision making, strong skills base, 
flexible human resource practices and quick resource appropriation and also manage their functional 
weaknesses during the course of delivery of cost-effective, inclusive and quality health provision. 
 
This paper has also established that across the study countries, there is no consensual definition for 
PPPs nor is the terminology necessarily universally applicable, as other authors have also noted. The 
authors were in agreement with the dominant notion underpinning PPPs which is about ‘… working 
arrangements based on a mutual commitment (over and above that implied in any contract) between 
a public sector organisation with any organisation outside of the public sector (Bovard, 2004)’. This 
broad conceptualisation allowed the study informing this paper to capture different configurations 
associated with the PPP model recognising that PPP actors cut across a range of sectors and roles 
including, pharmaceutical manufacturing, policy design, implementation, activism, procurement and 
supply chain and policy monitoring and evaluation.  
  
While policymakers and governments must contend with the sheer complexity and uncertainty of the 
nature of global health challenges, especially under conditions of economic constraints and difficult 
geographies which are commonplace in the historically disadvantaged settings of the study countries, 
the key drivers for PPPs established by this study include, but are not limited to the following:  
1. Partnerships are better placed to address market deficiencies, through risk sharing, across 
multiple stakeholders and projects, which is especially relevant in contexts of emerging 
technologies and innovations for whom the associated ‘high technical risk’ may outweigh the 
visible economic benefits 
2. Partnerships also aid economies of scale, particularly of procurement, service provision but 
also research and development and manufacturing 
3. PPPs are also viewed as ‘system integrators’ in which knowledge and ideas are leveraged 
across sectors, for instance across, industry, academia and government as seen in the 
examples of partnerships for in the areas of health financing, access to antiretroviral (ARV) 
drugs for HIV, and market access for diagnostics and treatments across the continuum of care 




Exemplifying the above, this paper has presented and analysed various configurations of PPPs, 
including various partnerships with two or more partners drawn from non-governmental 
organisations (NGOs), donor agencies, industry, and other for-profit and non-profit enterprises, 
academia and social enterprises which link with governments to address specific maladies, intra-
system issues, as a route to achieving better and a more responsive and resilient health system. This 
paper speaks broadly to the roles of PPPs in addressing global health inequity through market 
adjustment, connection of pharmaceutical suppliers with poor populations in low-middle income 
countries to drive overall health social inclusion, unpacking an array of context-specific social, 
economic, political, geographic, and epidemiological factors which cannot be successfully examined if 
the lens is not anchored on the sub-regional, regional and global political economies. The paper has 
thus expanded literature for the southern African region which hitherto disproportionately focused 
on public-private engagement in South Africa, with very little known about the other countries, 
outside of Zimbabwe and Mozambique, in which narratives on the health-industry complex from the 
perspectives of pharmaceutical manufacturing have only been recently captured (Mackintosh et al., 
2016). 
A number of specific conclusions and recommendations arise from this work pertaining to the key 
questions underpinning the study: 
 
a) The extent to which PPPs are prevalent in the health industry complex, across health 
innovation, manufacturing, and innovative financing mechanisms including the ways in 
which these elements drive health social inclusion.  
 
This paper has identified and analysed different examples on the distribution and make up of PPPs 
across different functional areas in the health sectors of the study countries. The case studies 
presented have showcased how the potential avenues for advancing government’s efficiency in health 
spending, deploying and leveraging the private sector (profit and non-profit) resources and human 
resources and skills, the effectiveness of private and public sector engagements in the health-industry 
complex, can be maximised. We recommend continuous appraisal and documentation of the role and 
contributions of different actors to PPPs, for example, how, as evidenced in this paper, government 
can support local pharmaceutical production and hence the local health-industry complex through 
innovative procurement by assuring markets for products; how public funding of research in 
universities and state innovation institutes de-risks the early stages of innovation and technology 
development thereby supporting a richer translation pipeline. However, there is need to invest in 
capabilities and resources for coordination in order for the broad range of benefits from partnerships 
to be realised. This includes recognition, as exemplified in our cases, of the technological, 
geographical, social as well as formal but also informal nature of partnerships, all of which separately 
or collectively can be good for impact, sustainability, agility, appropriateness and inclusion. 
 
b) The peculiar contextual realities of PPPs in the health industry particularly in those 
countries in which such factors remain markedly under-researched. 
 
This study has established that PPPs in health are distinct from typical infrastructure projects for a few 
key reasons. Apart from the transient and predominantly philanthropy driven nature of PPPs in some 
of the study countries, this study also established cases where health PPPs do not fit into the 
conventional models of PPPs (e.g. BOT or BOOT), yet still being within the conventional reasons why 
PPPs are initiated, e.g. to fill gaps in supply. We have also seen in the cases some PPPs whose 
motivations go beyond this in their design and/or in their operations.  What stands out for health PPPs 
is that primarily, private revenue contribution is usually low, and as a result, these projects require a 
large and ongoing payment from the government. In addition, the ongoing expenses of operating a 




infrastructure project in which capital expenditures (Capex) are the main cost element. Thus, there 
must be money and other resources for the project post-construction phase.  
 
c) The set of factors limiting the effectiveness of governance, incentive and policy 
frameworks to make the health system more adaptable, and responsive to health systems 
strengthening initiatives and articulation of the role of innovative health technologies 
within and across this sphere 
 
This paper established the existence of different mechanisms for governing and incentivising PPPs in 
the study countries. We established and recommend continuous recognition of the fact that 
Governments assume multiple roles as regulators, facilitators, funders of innovation and as well as 
investors in PPPs. These multiple roles could be leveraged for identification and deployment of much 
needed political champions for PPPs in the study countries. Further, we noted the catalytic role that 
PPPs play, and how they serve as sources of collateral capacities for new partnerships and for other 
sectors of the economy. Successful PPPs such as Biovac have shown ability to collaborate with both 
private and philanthropic actors in pursuing technology transfer and technological learning. The 
government as in the case of Biovac can, through departments such as DST, act as both brokers and 
integrators actively supporting the creation of an innovation ecosystem in the local production of 
pharmaceuticals. Such pervasive impact and potential should be harnessed for structuring incentive 
structures and governance mechanisms which are responsive and able to enhance the relevance and 
contributions of PPPs to health system strengthening.  
 
d) Indicators/metrics that would lend themselves well for the effective monitoring and 
evaluation of health system strengthening and financing arising from PPPs.  
 
We recommend that whilst the argument underpinning the need for metrics is self-evident, it is 
perhaps more prudent to ask how the technological, intellectual, industrial, and research-driven 
insights drawn from the PPP model can be effectively mobilised to tackle and meet current and future 
health demands through addressing the most pressing structural and functional limitations of health 
systems in these countries. In so doing, important contributions will be made towards nuanced 
context-specific narratives, rather than predominantly quantitative ideological argumentations 
critiquing the PPP model in health delivery.  To operationalise the above, we recommend a Partnership 
Impact Index which SGCI and SADC could develop to offer annual awards for impactful partnerships 
in some of the pressing and persistent health challenge areas, eg. HIV/AIDS. This could also potentially 
include a proactive dimension identifying, nurturing and rewarding innovative partnerships that are 
helping countries to cope with NCDs. A related idea would be the development of partnership/partner 
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Health and Industrialisation in Southern Africa (HISA) Study 
 
By 
African Centre for Technology Studies (ACTS) and The SCINNOVENT Centre 
 
Background 
The Science Granting Councils Initiative (SGCI) is a five-year Initiative, which aims to strengthen the 
capacities of Science Granting Councils (SGCs) in sub-Saharan Africa in order to support research and 
evidence-based policies that will contribute to economic and social development. The objectives of this 
initiative are to strengthen the ability of Councils to (i) manage research; (ii) design and monitor research 
programs based on the use of robust science, technology and innovation (STI) indicators; (iii) support 
knowledge exchange with the private sector; and (iv) establish partnerships between Councils and other 
science system actors. The Initiative is jointly funded by the United Kingdom’s Department for 
International Development (DFID), Canada’s International Development Research Centre (IDRC), and 
South Africa’s National Research Foundation (NRF).  
Theme 3 of the SGCI focuses on strengthening partnerships between Africa’s science granting councils 
and the private sector, with the ultimate objective to: (a) enhance knowledge exchange between 
academia and industry and (b) stimulate private sector investments into research and innovation. 
Theme 3 is being implemented by the ACTS Consortium comprising the African Centre for Technology 
Studies (ACTS), The Scinnovent Centre, the Science, Technology and Innovation Policy Research 
Organization (STIPRO) and the Association of African Universities (AAU). One of the crucial 
assignments for the Theme 3 of the SGCI is to commission three regional research studies critical to 
Public-Private Partnerships (PPPs) in Africa. 
Commissioned studies 
Among the key challenges that the SGCI sought to address is the entrenched mutual reluctance from 
academia and private sector actors in Sub-Saharan Africa (SSA) for research and innovation 
collaboration. Often times, the private sector actors complain that academic institutions are often too 
bureaucratic and inflexible in their operational procedures. They also contend that academic research 
in Africa is often too abstract or ‘out of touch’ and as a result, it increasingly fails to address commercial 
needs or local challenges.  On the other hand, academics accuse the private sector of being too profit-
focused; unstructured, institutionally weak and too small to engage in any meaningful R&D or innovation 
collaborations. This study falls under the "Public-Private Partnerships in Research and Innovation" 
strand of work, focuses on Health Systems in Southern Africa (with a special focus on the nexus 
systems strengthening/financing and pharmaceutical industrialization), with the following aims:  
✓ identify, analyze and share the subtle lessons behind the success of some of partnerships 
and collaborations between academia and industry while at the same time exposing the 
challenges that face the partnerships,  
✓  identify and highlight key areas of (a) mutual interests (b) disagreements/ “points of 
conflict” that either ‘glued’ together the partnerships or made them break apart, 
✓  interrogate the institutional and governance architecture of the partnerships and how 




✓ map out the unique policies, processes, practices that may have led to the success or 
failure of the partnerships, 
✓  tease out lessons/action guides for the science granting councils on how to catalyze, 
manage and enhance knowledge exchange between the academia and the private sector 
Purpose of this Questionnaire 
This questionnaire seeks to gather key stakeholder views to identify context-specific insights to unpack 
how health and industrialisation in Southern Africa, in the context of public-private partnerships (PPPs) 
will be able to address issues of "competitiveness and social inclusion" while supporting local 
pharmaceutical production interlinked with a mutually-supportive health-industry complex that fosters 
economic and social development. The results of the study will be used to produce a commissioned 
paper, Policy Brief and peer reviewed policy-oriented journal articles, which will inform policy, debates 
and potentially lead to reviews and re-organization of the health-industry arena in African countries.  As 
a key stakeholder in health, finance, industry and allied areas in the study countries and beyond, we 
seek your contribution to this endeavour through responding to this questionnaire. All responses will be 
anonymised in the analysis and project publications. You will however be included in the distribution 
lists for the study outputs towards the end of 2019.   
 
1.0 Respondent details 
 
1.1 Name (optional):………………………………………………….. 
1.2 Organisation:…………………………………  
1.3 Position in organisation:…… ………………………………….. 
1.4 Years in position:…………………………………………………… 
 
1.5 Stakeholder category:  
 
Government/Policymaker   
R&D organisation   
Academic institution     
Funding organisation    
Pharma company/supplier   
Continental/global agency    
Other (please specify)   
 
2.0 Considerations on peculiar contextual realities of PPPs in health-industry 
complexes 
• What historical factors favour private-public partnerships in the country’s 
economy, generally and with specific reference to health systems and 
pharmaceutical industries? 
• What current factors/opportunities necessitate the need for PPPs in the health-
industry complex? 
• Are there any constraining factors/challenges currently and in the future? 
• How can these be resolved? 














3.0  Prevalence of PPPs in health-industry complexes and their role in inclusion 
 
• Please give a few examples of successful PPPs in the national economy and 
reasons why they have been successful. 
• Are there any specific examples of PPPs in health systems and the 
pharmaceutical industry? Give examples 
• Where has the greatest impact of the PPPs been with respect to inclusive 
health care? 
o Affordable medicines, vaccines and diagnostic services 
o Widespread access to medicines, vaccines and diagnostic services 
o Timely access to medicines, vaccines and diagnostic services 
o Improved quality of medicines though GMPs 
o Other (specify) 
• Where has the greatest impact of the PPPs in the health-industry complex? 
o Local research, innovation and skills development 
o Financing of services and activities  
o Local facility upgrading and capacity utilisation 
o Technology transfer and acquisition of intellectual property 
o Other (specify) 
 
4.0 Evidence of qualitative and quantitative contribution of PPPs to improvement of 
healthcare access and functions in local health security 
o Which examples or specific cases highlight the key roles played by PPPs in 
the health-industry complex? 
o What is the source of corroborating evidence for this? 
o What qualitative factors makes these examples important (e.g. sustainability 
of PPPs, number and type of partners involved, unique business models, 
geographical reach of products, goodwill and relevance to local context, 
corporate social responsibility etc) 
o Please elaborate on some of the points raised 
o What quantitative factors make these examples important (e.g. market share, 
range of products, number of employees etc) 
o Please elaborate on some of the points raised.  
 
5.0 Governance, regulatory, financing and policy frameworks for anticipative, 
adaptable and responsive operation of PPPs in health-industry complexes 
o Who are the key actors in (a) regulation and (b) financing of health systems 
and pharmaceutical companies in the country? 
o What changes have occurred in these roles in the last 10 years? Why? 
o With respect to governance (including standards), financing and incentives for 
PPPs, how would you characterise (in your own words) the roles of national 
government, industry associations, WHO, NEPAD Agency, SADC and donors 
in these issues? 
o Are the governance mechanisms in place conducive for both existing and new 
forms PPPs? Briefly explain why you say Yes or No 
o Are the incentives in place conducive for existing and new forms PPPs? Briefly 
explain why you say Yes or No. 
 
6.0 Monitoring, learning and evaluation of the role of PPPs in health-industry 
complexes 
 





• Please briefly explain how this mechanism works, including roles, 
responsibilities and connections with the health-industry arena 
• In your view, what are the key lessons for your country regarding the role of 
PPPs in health-industry complexes, health systems strengthening and 
financing? 
• Related to the above, what are the key lessons from your country regarding 
the role of PPPs in health-industry complexes, health systems strengthening 
and financing? 
 
7.0 Beyond PPPs, are there other forms of partnerships that are useful and 
effective? 
o Can you suggest other forms of partnership or business models that could work 
for the health-industry complex? 
o Would they be replacing or complementing PPPs? Reasons for your 
suggestion 
o Thinking about Science Granting Councils and other key others in innovation 
systems, please suggest some actions that you think they should take to 
catalyze, manage and enhance knowledge exchange between academia, 
public and private sectors. 
o Finally, what issues do you think have not being adequately attended to in the 
agendas on PPPs and health-industry complexes in Southern Africa? 
 
 
